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CAT Common arterial trunk 
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Haemolytic anemia, eleveted liver enzymes, low platelet 
count 
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ICSI Intracytoplasmatic sperm injection 
IQR Interquartile range 
IUGR Intrauterine growth restriction 
IVF In-vitro fertilization 
IVS Intervilluous space 
ISUOG International Society of Ultrasound in Obstetric and 
Gynecology 
LSOL Left-sided obstructive lesions 
MCA Middle cerebral artery 
MoM Multiple of the median 
MRI Magnetic resonance imaging 
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OR Odds ratio 
PAPP-a Pregnancy associated plasma protein A 
PE Preeclampsia 
PlGF Placental growth factor 
RSOL Right-sided obstructive lesions 
sFlt-1 Soluble Fms-like tyrosine kinase-1 
SGA Small for gestational age 
SLE Systemic lupus erythematosus 
SNAs Synticial nuclear aggregates 
SVDs Single ventricle defects 
TBV Total brain volume 
TGA Transposition of the great arteries 
TOF Tetralogy of Fallot 
TOP Termination of pregnancy 
TR Tricuspid regurgitation 
UA-PI Umbilical artery pulsatiliy index 
UK United Kingdom 
US Ultrasound 
UtA-PI uterine artery pulsatility index 
VEGF Vascular enfothelial growht factor 
VSD Ventricular septal defect 
WES Wide exome sequencing 
β-HCG Human chorionic gonadotropin 
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Study 1 Major cardiac defect and placental dysfunction at 11-13 weeks’ 
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Chapter 1 INTRODUCTION 
 
 
 
 
1.1 CONGENITAL HEART DEFECTS: BACKGROUND 
Under the name of congenital heart defects (CHD) goes a large set of structural and 
functional abnormalities whose origin take place in the period of embryogenesis, and 
that are summarized in Figure 1.1. 
 
 
 
Figure 1.1 Locations of heart malformations that are usually identified in infancy. Numbers in brackets 
indicate the birth prevalence per million live births. Abbreviations: CoA, Coarctation of the aorta; AS, aortic 
stenosis; ASD, atrial septal defect; AVSD, atrioventricular septal defect; Ebstein, Ebstein anomaly; HLH, 
hypoplastic left heart; MA, mitral atresia; PDA, patent ductus arteriosus; PS, pulmonary stenosis; PTA, 
persistent truncus arterious; TA, tricuspid atresia; TGA, transposition of the great arteries; TOF, tetralogy of 
Fallot; VSD, ventricular septal defects; SV, single ventricle (From Fahed AC et al. Genetics of congenital 
heart disease: the glass half empty. Circ Res. 2013 15; 112:707-720). 
 
 
 Congenital heart defects and placental dysfunction 
 
 
 
 12 
CHDs are the most common type of congenital defects accounting for one third of all 
major congenital defects and occur in ~1% of live-born children (Matthiesen et al, 2016). 
CHDs represent an important medical challenge both in prenatal diagnosis, due to the 
required expertise in prenatal ultrasound for the correct diagnosis of the defect, and in 
the postnatal management, since part of these malformations requires a prompt 
intervention in the very first days of neonatal life.  
 
The causes of CHD are still largely unknown. Chromosomal and single gene defects 
affect up to a quarter of all cases of CHD leaving the majority without an apparent 
explanation. Is it possible that more than half of CHDs is caused by casual “errors” during 
the embryogenesis or could it be that intervening external factors are able to disrupt the 
normal cardiac development causing the malformation?  
 
Multi-factorial etiology, including environmental and epigenetic factors, could have a role 
in the pathogenesis of these “unexplained” cases, however it is still unclear how these 
factors interact to determine the disease. However, studying the early weeks of 
embryogenesis, when most of the fetal structures complete their morphogenesis, is 
difficult due to a lack of non-invasive techniques that allow studying the embryo in this 
time-frame.  
 
In recent years, researchers shifted their attention to the first trimester of pregnancy as 
the time in which pregnancies at risk to develop subsequent complications, like 
preeclampsia, can be identified and an intervention can be started (Rolnik et al, 2017). 
Placenta can be thought as a bridge connecting the mother and the fetus and, therefore, 
by studying maternal blood we can gather several information on placenta and fetal 
health: regarding the matter of our discussion, the concentration of angiogenic and anti-
angiogenic factors in maternal blood can give us information on placental function and 
some evidences show that an imbalance of these factors is present in fetuses with CHD 
(Llurba et al, 2013). 
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1.1.1 Genetic, epigenetic and environmental factors 
 
Un underlying parental genetic cause is known to be one of the causes of CHD: a positive 
family history, defined as the presence of a CHD in a first-degree relative, increases the 
risk for the current offspring of being diagnosed with a cardiac defect and is one of the 
indication for a detailed fetal echocardiography.  If one of the parents is affected the risk 
of having a child with a cardiac anomaly is 10.7% (Huhta et al, 2013). If a previous child 
had a heart abnormality the recurrence risk in the subsequent pregnancy is between 1 
and 4% but it is 3 to 4 times higher if two previous children were affected (Huhta et al, 
2013). It is, therefore, evident how much the familiar background is determinant for the 
onset of CHDs, however the exact genetic risks have been difficult to identify since 90-
97% of subsequent pregnancies after an affected child proceed without recurrence 
(Huhta et al, 2013).  
 
The genetic cause for each specific type of cardiac abnormalities is heterogeneous and 
seems that genetic factors, together with epigenetic and environmental factors, are 
responsible for the cause of CHD. However, the way in which environmental and 
epigenetic factors interact with genes remains poorly understood.  
Chromosomal and genetic abnormalities are a well-known risk of CHD and the incidence 
of chromosomal abnormalities is around 18-22% (Jansen et al, 2015). The most frequent 
chromosomal abnormalities are trisomy 21, trisomy 18, trisomy 13 and monosomy X. 
 
Microdeletion or microduplication genes syndromes are also involved in CHD. The most 
frequent is the 22q11 deletion, also known as DiGeorge syndrome, typically associated 
to conotruncal heart defect and linked to the haploinsufficiency of three genes (TBX1, 
CRKL, and ERK2) which causes dysfunction in the neural crest cells and anterior heart 
field, acting through gene inactivation, altered gene expression, or by encoding non-
functional proteins (Momma 2010). Other genetic conditions frequently associated with 
CHD are the Williams-Beuren syndrome, also known just as Williams syndrome, due to 
a microdeletion the q11.23 region of chromosome 7 that encompass the elastin gene 
(ELN), and monogenetic defects, like Noonan syndrome (Jansen2015).  
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The importance of identifying a chromosomal or a genetic defect in fetuses with CHD is 
related to a higher risk of associated neurodevelopment delay (NDD). However, the 
majority of heart defects still remains without a clear genetic or chromosomal cause in 
the background.  
 
The introduction of new technologies in the genetic analysis, like single nucleotide 
polymorphism array, next-generation sequencing and copy number variant (CNV) 
platforms are widening the range of known genetic causes of cardiac malformation. This 
is of crucial importance when counseling the parents. A recent meta-analysis on the 
clinical contribution of array comparative genomic hybridization (aCGH) reported that, for 
isolated CHD and after karyotyping and 22q11 FISH analysis, the incremented yield was 
3.4% (95% CI; 0.3-6.6%), while it was 9% for non-isolated CHD (Jansen et al, 2015). 
Whole exome sequencing (WES) analysis in familial cases of CHD with Mendelian 
inheritance without a previous known genetic cause is able to identify a likely pathogenic 
and pathogenic mutation in 33% of cases (LaHaye et al, 2016). 
 
However, some isolated CHD does not follow a familial inheritance and analysis of 
exome sequencing in children affected by CHD found that de novo point mutations are 
present in several hundreds of genes that collectively contribute to 10% of severe CHD 
(Fahed et al, 2013). New hypothesis to explain the occurrence of de novo mutations are 
based on epigenetic and environmental factors that can alter the genetic background. 
Maternal/placental microenvironment prior to and within 5-8 weeks of conception may 
influence the development of the fetal organs, such as heart and central nervous system. 
Environmental factors that can interfere with early heart development are different and 
include: 
- environmental teratogens (i.e. dioxin, pesticides); 
- maternal exposure (alcohol, isotretinoin, thalidomide, anti-epileptic drugs); 
- infectious agents (i.e. rubella);  
- folate deficiency; 
- maternal pre-gestational diabetes. 
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Maternal diabetes is a well-recognized risk factor for cardiac abnormalities associated 
with a 4-fold increase in offspring of CHD (Oyen et al, 2016). It has been suggested that 
maternal hyperglycemia could alter the normal process of embryogenesis, but a 
population study on around 2 million births over a 34-year period, showed that 
improvement in perinatal care did not change significantly the rate of CHD. Therefore, 
other factors, like obesity, increased maternal age and pro-inflammatory state, can 
contribute to the strong association with heart defect in diabetic mothers. Gestational 
diabetes, on the opposite, is not associated to an increased risk of CHD, supporting the 
idea that an abnormal embryonic environment is responsible of the onset of CHD, maybe 
inducing epigenetic modification of CHD related genes (Oyen et al, 2016).    
 
DNA methylation and histone modification are the most known epigenetic modifications 
that change chromatin regulation and thus genes expression (Chan et al, 2012). 
Epigenetic regulation of gene expression is one of the mechanisms involved in fetal 
programming. Specific gene can be activated, silenced of modulated by small non- 
coding RNAs (microRNA), DNA methylation status and histone modifications (Feinberg 
2007). In the early embryo, DNA after fertilization undergoes progressive demethylation 
and becomes hypomethylated during the pluripotential stages.  DNA methyltransferases 
are the enzymes responsible for DNA methylation. A principle source of methyl groups 
in the cell is S-adenosylmethionine synthetized by the folic acid metabolic cycle. Studies 
on mouse embryo showed that the observed cardiac defects are preventable if an 
adequate supplementation with folic acid is supplied early after conception and possibly 
at higher dose than the recommend multivitamins (Huhta et al, 2013). Therefore, 
epigenetic is an important area for analysis in relation to birth defects.  
 
Given that a high percentage of pregnancies are unintended, the mechanism of action 
of external factors, such as folate intake, and intersecting pathways during early 
gestation together with prophylactic mechanism involving epigenetic effects are critical 
in understanding the placenta-heart axis.  
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1.1.2 Placental factors 
 
Early in human gestation following conception, the fertilized embryo implants in the 
uterine wall. The successful implantation requires adequate maternal uterine perfusion 
and endogenous hormone preparation to allow initial embryonic survival and later organ 
development and growth for a term gestation.  
 
Shortly after implantation cardiomyocytes specification and commitment take place 
between days 16 and 19 post conception. The circulation and a beating tubular heart are 
established by 21 days post conception in human pregnancy. Next, a beating, linear, 
tubular heart forms that then loops and septates to form a four-chambered heart (4-6 
weeks of human gestation). Human cardiac morphological development is complete by 
53 days post conception (8 weeks of human gestation) (Figure 1.2).  
 
Figure 1.2 Embryonic development from day 2 to week 8, when development of the  
28 days 30 days 
36 days 44 days 
49 days – 53 days 
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heart is completed (taken from 
http://www.embryology.ch/anglais/iperiodembry/carnegie02.html). 
 
Initial steps in placentation occur in relatively low oxygen ambient, since in the first stages 
there is no maternal blood flow in the developing placenta. Histological studies on 
placentas of human early pregnancy (from 43 to 130 days of gestation) showed that 
before 8 weeks of pregnancy aggregates of cytotrophoblast cells virtually occlude the 
mouths of the maternal spiral arteries, ensuring that any flow into the intervillous space 
is a slow seepage of blood flow or even plasma filtrate. Only after this period direct 
channels can be observed, with increasing size and delineated shape after 11-12 weeks 
(Burton et al, 1999). These findings, published back in 1999, were recently confirmed by 
a study in which microvascular filling of the intervillous space (IVS) was demonstrated 
by contrast-enhanced ultrasound, giving an intravenous infusion of lipid-shelled 
octofluoropropane microbubbles, from 6 weeks onwards in 34 pregnant women: results 
showed that there is an increasing blood flow to the IVS starting from 6-7 weeks (Roberts 
VHJ et al, 2017).  
 
But how the development of the embryo can happen in this under perfused environment? 
There are evidence that, at this stage, low levels of oxygen are essential to the normal 
development of the embryo for two reasons: the first is that the system is still immature 
to protect itself from oxidative agents; the second is that it represents a trigger for 
angiogenesis stimulating the production of vascular endothelial growth factor (VEGF), 
placental growth factor (PlGF) and angiopoietin essential to the growth of the villous and 
harborization of the villous tree (Charnock-Jones et al, 2000).  
 
At later stages, physiological remodeling of the spiral arteries provides adequate blood 
supply increasing O2 concentration that is essential for the normal development of the 
fetus: chronic states of hypoxia or sudden increased concentration of O2 can alter the 
normal development of embryonic tissue in these early stages. Studies on animals 
proved that exposure of mice embryos to reactive oxygen species increased the risk of 
congenital abnormalities (Dennery 2007). It, therefore, seems that a normal embryonic 
development depends on a correct balance of O2 levels and either too low or too high 
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oxygen concentrations could damage the embryonic development.  A normal fetal-
placental homeostasis is guaranteed by O2 concentration and by the consequent 
production of angiogenic factors that promote formation of the highly arborized vascular 
bed. There is evidence from animal studies that angiogenic factors may be implicated in 
cardiac morphogenesis (Llurba et al, 2013).  
VEGF has many direct actions on endothelial cells, which are in some ways linked to the 
process of angiogenesis, and include vasodilatation, increase in micro-vascular 
permeability, protease release, migration and proliferation of endothelial cells and lumen 
foration. Studies on mice embryos have shown that it could also be involved in cardiac 
morphogenesis: VEGF expression is found in most endocardial cells located at point of 
cushion formation (Armstrong et al, 2004). In zebrafish embryos, blockage of VEGF 
receptors resulted in functional and structural defect of cardiac valve development, 
suggesting that these receptors are implicated in the formation of heart valves (Lee et al, 
2006). On the basis of these findings, Lambrechts et al. performed selective genotyping 
on 148 families with isolated TOF and showed that the presence of specific haplotype, 
the AAG haplotype, which lowers VEGF expression increases the risk 1.8-fold of 
Tetralogy of Fallot (TOF) and is transmitted in 61% of the affected children (Lambrechts 
et al, 2005). On the other side, a 2 to 3-fold overexpression of VEGF in mutant mice 
embryos was also found to result in severe abnormalities of cardiac development, 
including an attenuated compact layer of myocardium, overproduction of trabeculae, 
defective ventricular septation and remodeling of the outflow tract (Miquerol et al, 2000).  
 
VEGF production is increased as a response to hypoxia in order to recruit new blood 
vessels and improve cellular perfusion. Further studies on mice embryo showed that 
increased concentrations of VEGF secondary to hypoxia act as a teratogen factors on 
the heart, instead of being protective, thus increasing the rate of CHD (Dor et al, 2001). 
VEGF production seems to be regulated also by its most important antagonist, the 
soluble fms-like tyrosine kinase-1 (sFlt-1), which is highly expressed by trophoblast and 
could act as a protective agent when VEGF is overproduced (Charnock-Jones et al, 
2000). Ablation of the sflt-1 genes leads to aberrant angioblast commitment and 
inappropriate vascular channel development in chimeric embryos (Fong et al, 1999). 
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Therefore, VEGF expression is not only related to specific genetic background but 
depends also on environmental factors, supporting the multi-factorial etiology of fetal 
heart defects.  
PlGF, a glycoprotein belonging to the family of vascular endothelial growth factors 
(VEGF), is another important angiogenic factor produced by the placenta and induces 
proliferation, migration and activation of endothelial cells. PlGF is highly expressed by 
trophoblastic cells and is known to be involved in the regulation of placental vascular 
development. There is extensive evidence that in pregnancies with impaired placentation 
PlGF level, as well others angiogenic factors, is reduced and such a decrease is present 
from the first trimester (Tsiakkas et al, 2016). 
 
There is just one study so far, from Llurba and collegues, assessing the possible relation 
between PlGF concentration and CHD (Llurba et al, 2013). They showed that in fetuses 
with major heart defects the concentrations of maternal serum PlGF were significantly 
decreased compared to controls (p<0.0001), suggesting an impaired placental 
angiogenesis that is present since the first trimester of pregnancy. Notably, values of 
uterine artery pulsatility index (UtA-PI) were within the normal ranges implying that a 
normal perfusion on the maternal side is present (p=0.396).  The authors concluded that 
in fetuses with CHD there is a primary abnormal dysfunction of the placenta, reflected by 
lower levels of angiogenic factors, that seems to affect both placental and heart 
development and that is not related to abnormal placental perfusion. They, then, 
analysed PlGF according to three different subgroups of cardiac defect: valvar (32 
cases), conotruncal (25 cases) and left-sided defects (11 cases). Significant reduction of 
PlGF maternal serum blood concentrations was observed in the first two groups 
(p<0.0001 and p=0.003) but not in the last, where the small number of cases could 
explain the lack of significance (p=0.863). PAPP-a and beta-HCG maternal serum levels 
did not show any significant correlation with CHD (p=0.292 and 0.616, respectively). The 
conclusions are that, though lower levels of angiogenic factors are present in 
pregnancies with CHDs, this is not true for LVOT defects that may be a consequence of 
different pathogenic causes.     
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The presence of an unbalanced angiogenic status in fetuses with a CHD is also 
supported by histological findings from placenta tissue in newborns with hypoplastic left 
heart syndrome (HLHS): they documented a reduction in the numbers of terminal villi 
and reduced villous vasculature (p=0.001), lower expression of PlGF RNA (p<0.05), 
increased in Syncityal Nuclear Aggregates (SNAs) (p<0.01) and overall reduced 
placental weight (p=0.02) compared to controls (Jones et al, 2015). Therefore, in fetuses 
with CHDs, placenta fails to expand its villous tree and to develop terminal villi. Stanek 
found similar findings on a group of fetuses affected by what he calls “postplacental 
hypoxia”: in these cases, normal perfusion is provided on maternal side but the fetus 
does not have enough oxygen due to the presence of specific malformation like cardiac 
defects, umbilical knots, etc. He found thinner and longer villi due to poor branching on 
the placental side as a reflection of a compromised fetal circulation (Stanek 2015). 
Another larger study on 120 placental histology of 120 fetuses with CHD showed that the 
placental weight-to-birth weight ratio was significantly reduced in CHDs than in controls 
and histological findings of villous hypomaturity, thrombosis, chorioangiosis and 
placental infarction (Rychick et al., 2018).  
 
The same group of Llurba studied the expression of angiogenic and antiangiogenic 
factors in 65 fetuses with CHDs in fetal cord blood (39 cases), heart tissue of cases 
underwent to termination of pregnancy (TOP) (23 cases) and in maternal blood at the 
second and third trimester of pregnancy (65 cases) (Llurba et al, 2014). The results 
showed that, compared to controls, PlGF was significantly reduced (p<0.0001) and sFlt-
1 significantly increased (p=0.0438) in maternal serum, while in heart tissue and fetal 
cord blood sFlt-1 and VEGF were significantly increased but not PlGF. Interestingly, 
analysis of heart tissue of fetuses with CHD underwent to TOP showed an increased 
expression of sFlt-1 and transcript levels of proteins related to hypoxia, such as hypoxia 
inducible factor (HIF)-2a. Therefore, also in the second and third trimester there is a 
dysregulation of the anti/angiogenic status in the maternal blood and a degree of hypoxia 
in the fetal heart tissue associated to a prevalent antiangiogenic environment.  
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Linask et al., have introduced the concept of the “heart-placenta axis” (Fig. 1.3) based 
on the hypothesis that cardiac and placental abnormalities may coexist through 
polymorphisms in genetic developmental pathways common to both organs, in particular 
those regulated by Wnt/ß- catenin signaling, or through a lack of key micronutrients, such 
as folate (Linask et al. 2014).  
 
Figure 1.3 Figure of the heart-placenta axis, showing the vascular connections between the placenta and 
the fetus through multiple fetal vessel that constitute the fetal circulation: UC, umbilical cord; UA, umbilical 
artery; UV, umbilical vein; DV, ductus venosus; IF-OF: inflow-outflow; DA, ductus arteriosus (from Linask et 
al. Changes in vitelline and utero-placental hemodynamics: implications for cardiovascular 
development. Front. Physiol 2014. 5:390. 
 
The heart-placental axis is associated with parallel development of the placenta and 
heart that utilizes many common molecules and genes and reflects intimate and 
synergistic growth of both organs. 
However, as shown in Fig. 1.2, heart development is completed by around 8 weeks’ 
gestation before placental circulation has established.  
In an interesting review by Burton et al., on the relationship between human placenta 
and heart development, the authors stress the concept that in the first weeks of 
embryonic life the circulation is guaranteed by the presence of the yolk sac, as shown in 
Figure 1.4. 
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Figure 1.4 The extravillous 
circulations. The yolk sac is the first 
of the extraembryonic membranes 
to be vascularized, and likely plays 
a key role in maternal-fetal 
transport during the period of 
organogenesis before the chorionic 
circulation is fully established at ∼12 weeks. Changes in the 
resistance offered by each 
circulation may affect gene 
expression and differentiation of the 
fetal cardiomyocytes (From Burton 
et al. 2018)  
 
 
 
 
 
 
Extensive remodeling occurs toward the end of the first trimester when the definitive 
placenta is formed. Villi initially develop over the entire gestational sac but starting from 
around 8 weeks of gestation the villi over the superficial pole begin to regress, forming 
the smooth membranes or chorion laeve. Regression is associated with the progressive 
onset of the maternal arterial circulation to the placenta, first in the periphery and then in 
the rest of the placenta. This process is mediated by the migration of extravillous 
trophoblastic cells (EVT) into the placental bed and modulated by locally high levels of 
oxidative stress within the villi (Jauniaux et al., 2003).  
Events at this stage of development play a key role in determining the final size and 
shape of the placenta, and so may impact development of the fetal heart.  
 
1.2 Congenital heart defects and nuchal translucency 
 
Nuchal translucency (NT) is a well-recognized marker for CHDs. In a study on almost 
30000 pregnancies, including 50 cases with major CHDs, the presence of a NT above 
 Congenital heart defects and placental dysfunction 
 
 
 
 23 
the 95th centile achieved a detection rate for CHD of 56% (Hyett et al, 1999). The 
prevalence of CHDs increases with increasing value of NT (3% for NT between 3.5 and 
4.5 mm and 20% for NT ³5.5 mm). No differences were found according to the type of 
CHD, however strongest associations were seen for left-sided lesions such as HLHS and 
CoA. These findings are supported also by other studies that show how an increased NT 
thickness constitutes a risk factor for CHDs independently from the nature of the cardiac 
defect (Atzei et al, 2005; Syngelaki et al, 2011).  
 
The relation between increased NT and CHDs is, however, not fully understood. Some 
authors advocate the presence of impaired diastolic function that leads to increased NT 
with a mechanism similar to that observed in severe cardiac dysfunction and fetal 
hydrops at later gestations, where a rise in systemic venous pressure and in hydrostatic 
pressure may lead to the accumulation of nuchal fluid in the first trimester (Hyett et al, 
1996). In support of this theory, it is known that tricuspid regurgitation (TR) and reversed 
flow in the ductus venosus (DV), both signs of impaired diastolic cardiac function are 
more frequent in fetuses with CHDs and increased NT. However, one study examined 
the cardiothoracic ratio and the left ventricular ejection fraction in fetuses with HLHS and 
isolated ventricular septal defects and increased NT in the first trimester: they failed to 
prove the presence of cardiac dysfunction, though the assessment was done in the 
second trimester and, therefore, transient period of cardiac dysfunction that caused 
increased NT cannot be excluded with certainty (Simpson et al, 2000). Furthermore, 
additional signs of heart failure, like pericardial and pleural effusion, edema, 
cardiomegaly and ascites are all usually absent and increased NT can be associated to 
several congenital abnormalities, other than just CHDs, suggesting that there are 
different pathogenic pathways to the presence of a CHD and increased NT.  
 
The possible correlation between increased NT and CHD was evaluated in a review 
where 3309 relevant genes in cardiovascular development and heart morphology were 
manually cross-checked with 105 relevant genes in lymphatic development in mouse 
embryos (Burger et al, 2015). All these genes were identified through a genetic search 
on Mammalian Phenotype Browser. Following the cross-check, 3399 of 3414 were 
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excluded as they were not a mutual gene involved in both cardiac and lymphatic vascular 
development. Consequently, 15 genes were identified as potentially mutual genes in 
cardiac and lymphatic vascular development. Mutations in all but one gene (Pik3ca) 
resulted in a cardiac defects, abnormal lymphatic development and nuchal edema. All 
genes were involved in the regulation of endothelial differentiation strengthening the 
hypothesis that abnormal endothelial differentiation, rather than cardiac failure, is the 
common etiologic pathway underlying both defects. No specific CHD was identified, and 
no specific gene was responsible for a specific CHD and this is similar to findings in 
clinical practice and previous studies on human fetuses with increased NT, that showed 
no relation between a specific cardiac defects and increased NT (Haak et al, 2005; de 
Mooji et al, 2010). The numerous potential interferences in this pathway explain the 
relative common phenotype of increased NT. However, the presence of a mutual genetic 
background could explain the strongest association between cardiac defects and nuchal 
edema, which is not marked for other fetal defects.  
 
Fewer evidences are available on how maternal serum angiogenic and anti-angiogenic 
status may influence NT in fetuses with a CHD. The only study that investigated on this 
aspect is the one from Llurba et al. where angiogenic factors in fetuses with CHDs in the 
first trimester were analyzed: despite the fact that PlGF is overall reduced in all CHDs 
compared to controls, when sub-analysis was performed based on the presence or 
absence of increased NT, they found that in the heart defect group there was a significant 
association between log10PlGF-MoM and delta NT (r = -0.307; p<0.0001) but this 
observation was not found in the control group. They, then, classified the cardiac defect 
group according to NT thickness, and only patients with abnormal NT had statistically 
significant lower levels of PlGF than did the control group (Figure 1.5) (Llurba et al, 2013). 
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Figure 1.5. Box-and-whisker plot of PlGF-MoM values in the control 
group and in fetuses with CHD classified according to normal or abnormal 
NT (From Llurba et al, 2013). 
 
These are the first data on a possible relationship between PlGF and increased NT 
in fetuses with CHD however the mechanism of interaction between these two 
entities has not been explained. VEGF genes play an essential role in the 
development of lymphatic endothelial cells from veins, and mutations in some VEGF 
allele cause dysfunction of lymph vessels and severe systemic edema (Shibuya et 
al, 2008). Since PlGF belongs to the family of VEGF the same action could be apply, 
however these conclusions remain speculative since no specific study was 
performed so far. 
 
1.3   Congenital heart defects and obstetric adverse outcomes 
 
1.3.1 Preeclampsia 
 
Different studies have shown that in pregnancies with impaired placentation, PlGF 
production is reduced from the first trimester and is related to specific complications 
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of pregnancy such as preeclampsia (PE) and fetal growth restriction (FGR) (Poon et 
al, 2008; Akolekar et al, 2011). However, in these cases, there is an impaired 
perivascular and endovascular trophoblastic invasion of the spiral arteries. As a 
consequence, spiral arteries fail to become low-resistance vessels, and this is 
reflected in increased resistance to flow in the UtA (Meekins et al, 1994). 
 
VEGF, PlGF and s-Flt-1 are highly expressed by cytotrophoblast cells and it has 
been shown that their expression is altered in placenta tissue of women with 
preeclampsia (Zhou et al, 2002). Thus, apparently, pregnancies at risk for 
developing PE and pregnancies with fetus affected by a CHD share similar 
imbalances in the placental angiogenic environment.  
 
Based on these findings, the relationship between fetal CHD and maternal PE has 
been recently investigated: in a retrospective study on 279 pregnancies with a fetal 
CHD, the onset of PE, subdivided as mild, severe and HELLP syndrome, was 
reported in 5.7% cases (Ruiz et al, 2016). In a cohort of almost 2 million Danish 
singleton pregnancies, Boyd et colleagues examined the possibility of a relationship 
between fetal cardiac defect and PE: CHD was present in 0.9% of this population; 
early preterm and late preterm PE was present in 0.2% and 0.3%, respectively; term 
PE was registered in 2-3% and gestational hypertension in 0.9% of pregnancies with 
CHD, respectively (Boyd et al, 2017). Results of this study showed that women 
carrying a fetus with a CHD have a 7-fold increased risk of developing early preterm 
PE and a 3-fold risk of late preterm PE, while the risk was lower for late PE and 
gestational hypertension. These data show that there is a strong correlation between 
impaired placental function and fetal CHD, which seems to be true for early-onset 
forms but not for the late one and is consistent regardless the type of CHD.  
Moreover, if the woman developed early preterm PE in one of the previous 
pregnancies the risk for the offspring of being affected by a CHD is eight times higher 
for preterm PE and three times for late preterm PE. Correlations with PE were 
proved also if a previous pregnancy was complicated by a fetal CHD: the risk of 
developing preterm PE was a two-fold higher and the risk for term PE was 25%. 
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Gestational hypertension didn't show significant impact in any of these cases. This 
study provides evidence that maternal PE and fetal CHD share a common pathway 
most likely linked to an endothelial dysfunction secondary to poor placental perfusion 
and placental insufficiency typical of earlier forms of PE, also known as “placental” 
forms. Unfortunately, due to the retrospective nature of the study, data on UtA-PI 
and maternal serum analysis of anti/angiogenic factors were not part of the analysis.  
 
To date, there is just one retrospective study that analyzed UtA-PI in pregnancies 
affected by a fetal CHD in the second and third trimester: no significant differences 
in UtA-PI Z-score were observed in CHD cases compared to controls but UtA-PI Z-
score showed a quadratic increase with gestational age in the whole population 
studied and 61% of cases had UtA-PI values > 95th centile at the end of the 
pregnancy. Any PE was reported in 5% of the total population studied but whether 
the occurrence was somehow higher in the group with increased UtA-PI was not 
specified (Ruiz et al, 2017). 
 
1.3.2 Fetal growth and neurodevelopmental delay 
 
The association between any type of fetal defect and fetal growth restriction is long 
time known. In 1987 Khoury et al., reported that the presence of an isolated 
congenital defect doubles the risk for the fetus of being small for gestational age at 
birth (RR=2.2) and that this risk further increases if two or more defects are 
associated (from 20.5% among those with two defects to 58.6% among those with 
ten or more defects) (Khoury et al., 1987). In the early era of prenatal diagnosis, the 
assessment of body proportionality was used to provide information on the 
underlying pathophysiologic changes of fetal growth restriction and, clinically, at 
least two types of intrauterine growth restriction (IUGR) were recognized according 
to the relationship between birth weight and length: IUGR with affected body length 
(symmetric intrauterine growth restriction) and intrauterine growth retardation with 
normal body length (asymmetric intrauterine growth retardation). The underlying 
pathogenetic mechanism was considered to be different for these two forms of 
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IUGR, with an early embryonic insult responsible for the early-onset symmetric form, 
while the presence of placental insufficiency would be responsible for the late-onset 
asymmetric one (Campbell et al., 1977; Trudinger 1985; Wagner et al., 2016; Dashe 
et al., 2000). Studies on fetal growth and Doppler have shown that growth restriction 
secondary to placental insufficiency is characterized by increased impedance to flow 
in the uterine and umbilical arteries as a result of reduced placental function, while 
growth restriction in fetuses with fetal malformations or chromosomal abnormalities 
is more frequently characterized by normal Doppler values of UtA-PI and slightly 
higher values of UA-PI (Snijders et al., 1993; Hiersch et al., 2018).  
 
In the Baltimore – Washington Infant Study in 1991 (Rosenthal et al, 1991) birth 
weight was studied according to different types of CHD and it was shown that weight 
at birth differs for each type of CHD and may depend on the fetal circulation 
determined by the defect itself. These findings were confirmed in a subsequent study 
by the same group (Rosenthal 1996). Fetal growth was analyzed in 4 types of CHD 
(TGA; TOF; HLHS; CoA) and they found that, overall, fetuses with CHD are smaller 
compared to controls, but the biometric parameters were different according to the 
type of CHD and consistent with the altered fetal circulation determined by the CHD. 
For example, fetuses with TGA, where deoxygenated blood is directed to the head 
and oxygenated blood to the body, had smaller head volume compared to the body, 
while fetuses with TOF, where there is a mixture of oxygenated and deoxygenated 
blood, were symmetrically smaller for all biometric parameters. 
Around 20% of fetuses carrying a CHD are SGA and the presence of a CHD 
increases the risk of fetal growth impairment by two to three times (OR: 2.09) (Malik 
et al, 2015). Fetal growth seems to be affected already from the second trimester 
with a relative growth slope in the subsequent trimesters and HC values being the 
most affected (Williams et al, 2015). The relationship between CHD and fetal 
smallness is still unclear but it is possible that there is a shared etiologic pathway.  
 
The importance of assessing fetal growth in fetuses with a CHD is related to the 
increased incidence of adverse outcomes in children that will undergo to either 
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corrective or palliative surgery: the degree of preoperative growth failure has been 
associated with longer time on the ventilator, difficulties in postoperative feeding, 
higher risk of infection, longer hospitalization time and poor postoperative growth 
catch-up. Furthermore, in a recent publication, from the EPICARD study group, there 
are evidence that being born SGA with a major CHD requiring surgery is significantly 
associated with lower cognitive score than in the non-SGA group (Calderon et al, 
2017). Therefore, intrauterine fetal growth is critically important in these fetuses and 
the presence of fetal growth restriction constitutes a negative prognostic factor 
especially for those cases in need of postnatal surgery. 
 
Improvements in mortality following surgery for complex CHD brought the attention 
on neonatal morbidities, such as neurodevelopmental outcome. 
Neurodevelopmental delay (NDD) is a well-established complication in newborns 
with CHDs. Different reports indicate that, in complex CHD, up to 50% of cases have 
NDD, which can be variable and involving different aspects such as mild 
impairments in cognition, fine and gross motor skills, executive functioning, visual 
construction and perception, social interaction and core communication skills 
(Marino et al, 2012) (Fig. 6). 
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Figure 1.6 A summary of the neurodevelopmental deficits observed in children who underwent 
corrective surgery for CHD (From Nattel et al., 2017).  
 
NDD has been usually attributed to perioperative conditions occurred during surgery 
resulting in cerebral hypoxia and thrombo-embolic events. However, more recently, 
different studies reported the presence of brain lesions at neuroimaging already 
before cardiac surgery as well as in cases where surgery was not performed (Khalil 
et al, 2016). Magnetic resonance (MRI) studies found that the most commonly 
observed lesions were white matter injury, periventricular leukomalacia and stroke. 
Such brain lesions are reported in 19-52% of cases (Brossard-Racine et al, 2016; 
Mulkey et al, 2014). Despite different factors, like extent and duration of cerebral 
desaturation prior to surgery and intra-operative hypoxia, are important determinants 
of neurocognitive outcomes, the question whether brain insult is already present 
before surgery has arisen (Nattel et al., 2017). The first studies on the assessment 
of NDD were carried out on TGA cases because of the relatively easy surgery 
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needed to correct these defects that shouldn’t expose to serious degree of intra-
operative hypoxia (Shillingford et al, 2008).  
 
There are two main theories to explain the presence of NDD in fetuses with CHDs: 
the first is based on genetic and epigenetic factors that could affect the normal 
development of the brain in the presence of a CHD and whether any alterations of 
these pathways leads to abnormal development of both organs, heart and brain, 
with increased susceptibility of the brain tissue to hypoxic insults; the second is that 
the presence of a cardiac defect causes various degree of hypoxia due to the 
pathological fetal circulation established that secondarily affects the brain (Hinton et 
al, 2008). Quite interestingly, various degrees of NDD are observed also in minor 
CHDs, like ventricular septal defects (VSD) not requiring surgery (Khalil et al, 2016). 
Advanced MRI techniques have allowed the measurement of brain metabolism, 
cortical development and cerebral oxygenation. Some studies showed a progressive 
decline starting in the 3rd trimester, with reduced cerebral oxygenation and 
metabolism, smaller brain volumes and delayed cortical gyrification 
(Limperopoulous et al., 2010; Clouchoux et al., 2012). In Figure 7 we can see how 
the Total Brain Volume (TBV) decreases with advancing of gestational age and the 
third trimester (~ 28 weeks, red arrow) seems to be the critical period when high 
energy dependent process happening in the fetal brain meet conditions that restrict 
cerebral oxygen or substrate supply (Limperopoulous et al., 2010).  
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Figure 1.7 Relationship between gestational age and Total brain 
volume (TBV) in fetuses with CHD (open circles) and controls (solid 
diamonds) (From Limperopoulous et al. Circulation, 2010) 
 
Therefore, the third trimester seems to be the most sensitive time of gestation for 
brain maturation including neuronal migration and arborization, synaptogenesis, 
programmed cell death, oligodendrocyte maturation, and extensive reorganization 
of synaptic connections. McQuillen et al. suggest that structural brain abnormalities 
in CHD are related to alterations in cerebral blood flow at key moments in 
development (McQuillen et al., 2007). They suggest that damage occurs as a result 
of a unique vulnerability in late oligodendrocyte progenitor cells and subplate 
neurons, which play a critical role in myelination and white matter track development 
and are particularly vulnerable to hypoxia-ischemia. Myelination is energy-
consuming, and oligodendrocyte precursors release self-inhibitory signals if energy 
demands aren’t met. Fundamental cerebrovascular abnormalities in CHD brains 
may cause focal arrest of cells that a) inhibit appropriate myelination and b) are 
susceptible to vascular insult, contributing to white matter injury. In Figure 8 there is 
a schematic representation of the pathophysiology of neurodevelopmental deficits 
seen in CHD patients. 
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Figure 1.8 A schematic representation of the pathophysiology of neurodevelopmental 
deficits seen in CHD patients (From Nettel et al., 2017). 
 
Considering these emerging evidences that seems to collocate, in some fetuses with 
CHDs, the timing of the brain insult in the intrauterine life, different authors started 
investigating on US assessment of HC and blood flow to the middle cerebral artery 
(MCA) as prenatal parameters potentially able to identify fetuses at risk of NDD. The 
hypothesis on HC originated from the observation that neonates with a CHD are 
born with relatively smaller heads than normal babies and from the assumption that 
if in fetuses with CHDs there is chronic hypoxia because of the heart defect, brain 
volume would have been smaller and therefore the HC is smaller (Sun et al, 2015). 
The hypothesis on MCA-PI, and its ratio with the umbilical artery pulsatility index 
(UA-PI), is based on the findings in FGR fetuses.  
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FGR is most commonly caused by placental insufficiency, which exposes the fetus 
to a situation of chronic hypoxia. As a response to hypoxia the fetus redistributes its 
cardiac output to maximize oxygen and nutrient supply to the brain in a mechanism 
known as “brain sparing”.  This happens because the fetal circulation is a parallel 
circuit where the majority of the right ventricular output is shunted to the descending 
aorta through the ductus arteriosus while the left ventricle mainly supplies the upper 
body and the brain. In case of placental insufficiency there is vasoconstriction of 
peripheral vascular beds, due to placental damage, that increases the right 
ventricular afterload but, on the other side, the presence of vasodilation of the 
cerebral arteries, due to vasodilation of the MCA, causes a decrease in the left 
ventricular afterload. These changes result in a preferential shift of the cardiac output 
in favor of the left ventricle, enhancing blood supply to the brain in what is called 
cerebral redistribution (Coehn et al, 2015). Changes in cerebral blood flow can be 
detected by measuring MCA-PI and by its ratio with the UA-PI (cerebroplacental 
ratio; CPR) by Doppler ultrasound.  
 
The “brain-sparing” effect was considered a reactive mechanism in IUGR fetuses to 
protect the brain from hypoxia. However, there are evidence that the presence of 
either low MCA-PI or low CPR is significantly associated to adverse perinatal 
outcome and to increased risk of delay in neonatal motor and state organization, 
lower communication and problem–solving score at 2 years of age (Miller et a, 
2016).  
In CHDs the altered circulation secondary to the anatomic defects can lead to 
various degrees of hypoxia. Simplifying, there are at least three circulatory 
mechanism that appear to be impacting the oxygen content of blood supplied to the 
brain in fetuses with CHD, shown in Figure 9. 
 Congenital heart defects and placental dysfunction 
 
 
 
 35 
 
Figure 1.9 Oxygen saturations across the circulations of representative examples of a 
normal fetus and fetuses with hypoplastic left heart syndrome (HLHS), transposition of the 
great arteries (TGA) and tetralogy of Fallot (TOF) by MRI. In the normal fetal circulation, 
there is streaming of oxygenated blood from the placenta to the fetal cerebral circulation via 
the ductus venosus and foramen ovale. In each of the examples of CHD, this pathway is 
disrupted (from Sun et al., 2016).  
 
The first authors reporting on reduced HC values and MCA-PI in fetuses with a CHD 
in the third trimester were Donofrio et al (Donofrio et al, 2003). The study was 
conducted on 41 fetuses with CHD, divided in HLHS (12), TGA (4), TOF (11), left-
sided obstructive lesions (LSOL) (4) and hypoplastic right heart syndrome (HRHS) 
(5), compared to 22 controls at 34 weeks. The mean HC to fetal weight ratio (HC/Wt) 
was overall significantly altered in the affected group (p=0.09). Sub-analysis by each 
type of CHD showed that significance was reached just in TOF cases (p<0.03) and 
not in the others, including HLHS, while CPR was significantly reduced in all type of 
CHD apart from LSOL and TOF; MCA-PI, however, was not significantly reduced in 
HRHS and LSOL suggesting that, though UA had normal values there could be a 
contribution in the calculation of the CPR explaining these differences. In a 
subsequent study by Kaltman at, CHDs were divided into left-sided (HLHS, 28 
cases, and LSOL, 13 cases) and right-sided obstructive lesions (RSOL, 17 cases) 
and they found that MCA-PI was significantly reduced in HLHS (p<0.001) while 
MCA-PI was significantly increased (p<0.001) in RSOL compared to HLHS and also 
UA-PI showed significantly higher values compared to normal (p=0.045) (Kaltman 
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et al, 2005). They explain the higher MCA-PI values in RSOL to be due to auto-
regulation of the MCA to the increased blood flow directed to the brain in such 
lesions. The discrepancy in results with the article from D’Onofrio may be explained 
by the different number of cases included and the authors recommend caution in 
using CPR in fetuses with CHD because reference values were established in IUGR 
fetuses with a normal heart and they could not be of value in assessing fetuses with 
CHDs. 
 
Many other studies were published on this topic but there is a high degree of 
heterogeneity for type of study, inclusion criteria (like gestational age, biometric 
parameters analyzed), classification of the heart defect adopted.   
A recent meta-analysis on HC values report that in fetuses with a CHD a smaller HC 
is present with a value of only 0,5 SD below the population mean (Jansen et al, 
2016). Data on each type of CHD could not be evaluated because of the small 
numbers available for each category. Fewer data are available on AC and FL values.  
 
LVOT lesions, HLHS, TGA and TOF are the defects that were examined more 
frequently. MCA-PI and CPR were found to be lower in left-sided lesions, HLHS and 
TOF with the lowest values found in the HLHS groups (Ruiz et al, 2017; Masoller et 
al, 2016; Szwast et al, 2012; Kaltman et al, 2005; Yamamoto et al, 2013; Williams 
et al, 2012) while contradictory results were found for TGA: some studies reported 
lower values while other found similar values to controls (Ruiz et al, 2017; Jouannic 
et al, 2002; Yamamoto et al, 2013; Berg et al, 2009). Fewer studies evaluated MCA-
PI in right-sided lesions, but in two that specifically compared left and right-sided 
lesions with healthy controls, they found the presence of a reduced MCA-PI and 
CPR in left-sided and increased MCA-PI in right-sided lesions (Szwast et al, 2012; 
Kaltman et al; 2005). Contradictory results were reported also for the UA-PI because 
in some reports increased values of PI were reported in fetuses with CHD, while in 
others there were no significant differences (Kaltman et al; 2005; Meise et al, 2001; 
Szwast et al).  
Table 1 report a summary of the studies evaluated in this thesis.   
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Tab. 1.1 Summery of the literature 
Study (First 
Author, 
journal, Year 
of 
Publication) 
Study 
design, 
No. Infants 
CHD Age Methods Findings  
Ruiz et al, 
Ultrasound 
Obstet 
Gynecol, 2016 
Retrospective 
study, 
N= 119 
Mixed II and III 
trimester Ultrasound (biometry, 
Doppler) 
 
Normal MCA-PI and CPR 
during     second trimester; 
18% MCA-PI and CPR less 
than 5th percentile at 1st 
examination  
Lower MCA-PI in group with 
severe impairment of 
cerebral blood flow UA-PI 
increased with GA 
Hahn et al, 
Ultrasound 
Obstet 
Gynecol, 2016  
Retrospective  
study, N = 133  
SVA II and III 
trimester Ultrasound (biometry, 
Doppler) 
 
Lower MCA-PI and 
decreased more as GA 
progressed  
Smaller HC at 24–29 wk GA 
and >34      wk GA 
Fetal HC predictor of 
neonatal HC from 30 wk 
GA 
MCA-PI not associated with 
fetal and neonatal HC 
Zeng et al, 
Ultrasound 
Obstet 
Gynecol, 2015  
Case-control 
study,  
N = 73/168  
 
Mixed II and III 
trimester Ultrasound (biometry, 
Doppler) 
 
Lower MCA-PI 
Total intracranial volume, 
frontal lobe        volume, 
cerebellar volume, and 
thalamus volume 
progressively decreased 
from 28 wk GA 
Largest decrease in frontal 
lobe volume, followed by 
total intracranial volume 
and cerebellar volume 
Smaller HC and BPD from 33 
wk GA 
Zeng et al, 
Ultrasound 
Obstet 
Gynecol, 2015  
Case-control 
study,  
N = 112/112  
Mixed 20-30 
wks 
Ultrasound 
(Doppler) Lower MCA-PI in HLHS, MCA-PI tended to be lower 
in LSOL, normal MCA-PI in 
TGA and RSOL 
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  Higher cerebral blood flow, 
vascularization index, flow 
index, and vascularization 
fow index of the total 
intracranial volume and 3 
main arteries higher in 
HLHS and LSOL and of the 
anterior cerebral artery in 
TGA 
Masoller et al, 
Ultrasound 
Obstet 
Gynecol, 2014  
 
Case-control 
study,  
N = 95/95  
 
Mixed 20-24 
wks Ultrasound (biometry, 
Doppler) 
 
Lower MCA-PI and CPR and 
higher fractional moving 
blood volume 
Fractional moving blood 
volume >95th percentile in 
81% compared with 11% in 
controls 
No differences in MCA-PI 
and fractional moving 
blood volume between 
CHD diagnostic groups 
Smaller BPD and HC 
No differences in BPD and 
HC between CHD 
diagnostic groups 
Williams et al, 
Am Heart J, 
2013  
Cohort study, 
N = 134 
SVA 18-38 
wks Ultrasound (Doppler) 
MCA-PI at first fetal 
echocardiogram  −0.95 ± 
1.5 
22% MCA-PI < −2.0 at least 
once across gestation 
Yamamoto et 
al, Ultrasound 
Obstet 
Gynecol, 2013  
Case-control 
study, 
N = 89/89  
Mixed 32 wks Ultrasound 
(biometry, 
Doppler) 
Lower MCA-PI, higher UA-PI 
and lower CPR in HLHS 
and CoA 
CoA with retrograde aortic 
arch flow, lower MCA-PI 
and CPR, and higher UA-
PI compared with CoA with 
antegrade flow 
Normal MCA-PI, UA-PI, and 
CPR in TGA and POTO 
Smaller HC at birth in TGA 
and CoA 
Szwast et al, 
Ultrasound 
Obstet 
Gynecol, 2012  
Retrospective 
study,  
N = 131/92  
SVA 18-40 
wks Ultrasound (Doppler) 
Lower MCA-PI and lower 
CPR in aortic arch 
obstruction compared with 
controls and compared 
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with pulmonary obstruction 
 
MCA-PI decreased during 
gestation for aortic 
obstruction 
MCA-PI increased during 
gestation for pulmonary 
obstruction 
Normal UA-PI 
Williams et al, 
Ultrasound 
Obstet 
Gynecol, 2012  
Pilot study,  
N = 13  
 
Mixed 20-24 
wks Ultrasound (Doppler) 
MCA-PI −1.7 ± 1.1 
56% CPR < 1.0 (no z scores) 
HLHS and TOF lowest MCA-
PI (−2.4 and −2.01, 
respectively), TGA −0.75  
Arduini et al, J 
Matern Fetal 
Neonatal Med, 
2011  
Case-control 
study, 
N = 60/65  
Mixed 30-38 
wks Ultrasound (biometry, 
Doppler) 
Lower MCA-PI and CPR (no 
z scores) 
HLHS and CoA lowest and 
TOF and TGA highest CPR 
Smaller HC and HC/AC 
HLHS and CoA lowest and 
TOF and TGA highest 
HC/AC 
Itsukaichi et al, 
Fetal Diagn 
Ther, 2011 
Retrospective 
study,  
N = 44/140  
Mixed 28-34 
wks Ultrasound (biometry, 
Doppler) 
MCA-RI measurements more 
often less than 5th 
percentile and UA-RI >90th 
percentile 
Similar biometry 
measurements in fetuses 
<10th and >10th MCA-RI 
percentile 
Berg et al, 
Ultrasound 
Obstet 
Gynecol, 2009 
Case-control 
study, N = 
113/137  
 
Mixed 19-41 
wks Ultrasound (biometry, 
Doppler) 
Smaller HC at birth, normal 
MCA-PI and CPR in TGA 
Smaller HC at birth, lower 
MCA-PI and CPR in HLHS 
Normal biometry and Doppler 
parameters in PA, AoS, 
and TOF  
Guorong et al, 
Fetal Diagn 
Ther, 2009 
 
Case-control 
study, N = 
45/275 
 
Mixed 20-40 
wks Ultrasound (Doppler) 
Normal MCA-PI 
MCA-PI tended to be lower 
in LSOL and was lower in 
congestive heart failure 
Higher UA-PI and higher u/C 
PI ratios 
No traditional “brain 
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sparing” as MCA-PI was 
normal, whereas U/C PI 
was higher 
Kaltman et al, 
Ultrasound 
Obstet 
Gynecol, 2005 
Case-control 
study,  
N = 58/114  
 
Mixed 20-40 
wks Ultrasound (Doppler) 
Lower MCA-PI in HLHS 
Higher MCA-PI in RSOL 
compared with HLHS 
Higher UA-PI in RSOL 
Donofrio et al, 
Pediatr 
Cardiol, 2003  
 
Case-control 
study, 
N= 36/21 
Mixed II and III 
trimester Ultrasound (Doppler) 
Lower MCA-RI and CPR 
Normal UA-RI 
HLHS and HRHS infants had 
highest incidence of 
abnormally low CPR (58% 
and 60%) 
Jouannic et al, 
Ultrasound 
Obstet 
Gynecol, 2002 
Case-control 
study, 
N= 23/40 
TGA 36-38 
wks Ultrasound (Doppler) 
Lower MCA-PI 
 
Normal UA-PI, DV-PI, and 
Ao-PI (no z scores)  
Meise et al, 
Ultrasound 
Obstet 
Gynecol, 2001 
Case-control 
study, 
N= 115/100 
Mixed 19-41 
wks Ultrasound (Doppler) 
Normal MCA-PI 
Higher UA-PI 
No difference in UA-PI >95th 
percentile  
Masoller et al, 
Ultrasound 
Obstet 
Gynecol, 2016 
 
Case-control 
study,  
N = 116/116 
 
Mixed 30-38 
wks Ultrasound (biometry, 
Doppler) 
 
Lower MCA-PI and CPR and 
higher   fractional moving 
blood volume  
CHD diagnostic groups 
Smaller BPD and HC 
No differences in AC and 
FL between   CHD and 
controls 
Modena et al, 
Am J Obstet 
Gynecol, 2006 
 
Case-control 
study,  
N = 71/71 
 
Mixed 24-28 
wks Ultrasound (Doppler) 
Normal MCA-PI, UA-PI, and 
CPR 
MCA-PI more often less than 
5th percentile (5/71 vs 0/71) 
CPR more often less than 5th 
percentile (8/71 vs 2/71) 
No difference in UA-PI >95th 
percentile (6/71 vs 3/71) 
CHD, congenital heart defects; MCA-PI, middle cerebral artery pulsatility index; CPR, cerebro-
placental ratio; UA-PI, umbilical artery pulsatility index; GA, gestational age; AC, abdominal 
circumference; Ao, aorta; AoS, aortic stenosis; BPD, biparietal diameter; CoA, coarctation of the 
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aorta; DV-PI, pulsatily index of the ductus venosus; HC/AC, head circumference/abdominal 
circumference; HRHS, hypoplastic right heart syndrome; LSOL, left-sided obstructive lesion; 
POTO,  pulmonary outflow tract obstruction; RSOL, right-sided obstructive lesion; SVA, single 
ventricle anomaly; TOF, tetralogy of Fallot; U/C PI, pulsatility index of the umbilical 
artery/pulsatility index of the middle cerebral artery. 
 
 
Overall, as found in a recently published meta-analysis (Mebius et al, 2017), it can 
be concluded that the existing evidence suggest a tendency towards a brain 
vasodilation, as reflected by MCA evaluation, mainly in those cardiac defects with 
impaired blood flow to the brain. However, it is not clear whether the clinical meaning 
of these findings is the same as in SGA fetuses. 
 
Despite the efforts put in identifying markers of impaired intrauterine brain 
development in the presence of isolated major congenital heart defects, the 
controversial data from the studies published so far do not allow a proper counseling 
for each type of cardiac defects in the prediction of the risk of post-natal NDD.  A 
recent consensus statement from the International Society of Ultrasound on 
Obstetrics and Gynecology (ISUOG) recommend a cautious prenatal counseling of 
fetuses with CHDs since there is a lack of evidence in the relationship between 
CHDs, HC growth, prenatal Doppler evaluation and post-natal NDD (ISUOG, 2017).  
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Chapter 2 HYPOTHESIS 
 
 
2.1 Main hypothesis 
 
Isolated major CHDs are characterized by the presence of placental dysfunction. 
 
2.2 Specific hypothesis 
 
1. Placental dysfunction in fetuses with isolated major CHDs is reflected in an 
impaired angiogenic status since the first trimester of pregnancy. 
2. Placental dysfunction affects fetal growth in the second and third trimester of 
pregnancy. 
3. The combination of a fetal CHD and placental dysfunction is reflected in 
abnormalities of fetal-placental Doppler. 
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Chapter 3 OBJECTIVES 
 
 
3.1  Main objective 
 
To evaluate the correlation between isolated major CHDs and placental dysfunction and 
the impact on intrauterine growth and fetal Doppler throughout the pregnancy. 
 
 
3.2  Specific objective 
 
1. To evaluate the relationship between isolated major CHDs and markers of 
placental perfusion and function in the first trimester of the pregnancy. 
2. To evaluate the relationship between isolated major CHDs, fetal growth pattern 
and markers of placental perfusion in the second and third trimester of the 
pregnancy. 
3. To evaluate the relationship between isolated major CHDs, placental perfusion 
and fetal-placental Doppler (MCA-PI and UA-PI) in the third trimester of 
pregnancy. 
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Chapter 4 METHODS 
 
4.1 Study population 
 
The data for this study were derived from prospective screening for adverse obstetric 
outcomes in women attending for routine pregnancy care at King’s College Hospital and 
Medway Maritime Hospital, United Kingdom. The women were screened between March 
2006 and October 2015 and gave written informed consent to participate in the study, 
which was approved by the Ethics Committee. 
At the first visit, a complete recording of maternal demographic characteristics and 
obstetric and medical history was taken with measurement of maternal weight and 
height.  
The first trimester ultrasound examination was performed at 11-13+6 weeks’ gestation 
and included: measurement of the fetal crown-rump length (CRL) to determine 
gestational age (Robinson et al 1975), measurement of the fetal nuchal translucency 
(NT) thickness (Nicolaides et al 1994), examination of the fetal anatomy for the diagnosis 
of major fetal defects (Syngelaki et al 2011), and transabdominal colour Doppler 
ultrasound for the measurement of UtA-PI (Plasencia et al 2007). The policy of both 
hospitals for the anatomical evaluation of the fetal heart in the first trimester is to get a 
color-Doppler view of the 4-chamber and the confluence of the aorta and pulmonary 
artery also known as “V-sign” (Syngelaki et al., 2011). Maternal serum PAPP-A and free 
ß-human chorionic gonadotropin were sampled for combined screening for fetal 
aneuploidies (Nicolaides et al 2011), while maternal serum PlGF was sampled for 
research purposes.  
The second trimester ultrasound examination was performed at 20+0-23+6 weeks and 
included: estimation of fetal size from transabdominal ultrasound measurements of fetal 
head circumference (HC), abdominal circumference (AC) and femur length (FL) plus 
transabdominal color Doppler ultrasound for the measurements of the UtA-PI (Albaiges 
et al 2000). 
This scan involved systematic detailed examination of the fetus, including a sweep 
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through the heart in a transverse plane to include the four-chamber view, outflow tracts 
and three vessel view of the heart and great vessels with and without color Doppler. 
If a fetal abnormality was suspected, the case was examined by a fetal medicine 
specialist. Likewise, all cases of suspected fetal cardiac defect were examined by a fetal 
cardiologist. In addition, the cardiologist carried out a fetal echocardiography at 11-14 
weeks in those with NT values above the 99th centile and at 20 weeks in those with a 
NT between the 95th and 99th centiles. 
All cases with a normal second trimester scan were offered a routine third trimester scan 
at 36 weeks’ gestation while those with a diagnosis of CHD were offered serials growth 
scan at 24+0 - 28+6 weeks, at 30+0 - 34+6 weeks, and at 35+0 - 37+6 weeks. 
The ultrasound examination included, for both groups, estimation of fetal size from 
transabdominal ultrasound measurements of HC, AC and FL. Transabdominal colour 
Doppler ultrasound was used to visualize the umbilical artery (UA), the middle cerebral 
artery (MCA) and the UtA. Doppler parameters were recorded automatically from 
consecutive waveforms and measured during periods of fetal quiescence. An angle of 
insonation below 30° was employed. The UA waveform was recorded by assessing a 
single free loop of umbilical cord using the colour Doppler. The UA-PI was calculated by 
applying a standard formula (Acharya et al 2005). The MCA Doppler was recorded 
according to a standard protocol by obtaining a transverse section of the fetal head and 
identifying the vessel close to the circle of Willis using colour Doppler and pulsed-wave 
Doppler to assess impedance to flow and PI was measured when three similar 
consecutive waveforms were observed for all three vessels (Bahlmann et al. 2002; Vyas 
et al 1990).  
The left and the right uterine arteries were identified at the level of the crossover with the 
external iliac artery using colour Doppler (Albaiges et al., 2000). After identification of 
each UtA, pulsed-wave Doppler was used with the sampling gate set at 2 mm to cover 
the whole vessel. Care was taken to ensure that the angle of insonation was less than 
30◦ and the peak systolic velocity was greater than 60 cm/s to ensure that the UtA, rather 
than the arcuate artery, was being examined. When three similar waveforms had been 
obtained consecutively, the PI was measured, and the mean PI of the left and right 
arteries was calculated.  
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All neonates were examined by a pediatrician. Prenatal and neonatal findings were 
recorded in computerized databases. Data on pregnancy outcome from women who 
booked for obstetric care in our hospitals but delivered in other hospitals were obtained 
either from the maternity computerized records in these hospitals or the general medical 
practitioners of the women. 
 
4.2  Inclusion and exclusion criteria  
 
All cases with major cardiac defects diagnosed by pediatric cardiologists either 
antenatally and / or in the neonatal period were included if the subsequent criteria were 
met: 
- measurements of maternal serum PAPP-a, bHCG, PlGF levels in the 11-13 
weeks group and color Doppler UT-PI; 
- measurements of fetal biometry and UtA-PI in the 20-24 weeks group; 
- measurements of fetal biometry and UtA-PI, UA-PI and MCA-PI in the 30-38 
weeks group. 
Abnormalities suspected antenatally but not confirmed in the neonates were not 
included. In contrast, the prenatal diagnosis in cases of terminations and miscarriages 
at < 24 weeks or stillbirths at > 24 weeks were assumed to be correct because in these 
cases postmortem examination was not performed systematically. 
The following fetal cardiac defects were not included: firstly, ventricular septal defects 
not requiring surgery because they are generally not considered to be major defects, 
secondly, right aortic arch, persistent left superior vena cava and aberrant right 
subclavian artery because they are not supposed to cause fetal hemodynamic changes 
and thirdly, cardiac tumors developing during the second and third trimesters of 
pregnancy because these defects would not be expected to have any manifestations 
during the 11-13 weeks scan. 
All cases with aneuploidies and/or non-cardiac defects diagnosed prenatally or in the 
neonatal period were excluded as well as pregnancies with no abnormal fetal findings at 
the 11-13 weeks scan and / or the 20-24 weeks scan which resulted in termination, 
miscarriage or stillbirth and those lost to follow up. 
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4.3 Statistical analysis  
 
Data from continuous variables were expressed as medians and interquartile ranges and 
from categorical data as n (%). Comparison of the maternal characteristics between the 
outcome groups was by the χ2-square test or Fisher’s exact test for categorical variables 
and Mann-Whitney U-test for continuous variables, respectively. A p value of < 0.05 was 
considered significant. Post-hoc Bonferroni correction was used for multiple 
comparisons. 
For the first trimester the measured values of PAPP-A, PlGF and UTPI were log10 
transformed to make their distributions Gaussian and each value was expressed as a 
multiple of the normal median (MoM) after adjustment for those characteristics that 
provide a substantial contribution to the log10 transformed value. The measured fetal NT 
was expressed as a difference from the expected normal mean for fetal CRL (delta 
value). Median MoM values of biomarkers were compared between outcome groups. We 
divided congenital cardiac defects into those with fetal NT< 3.5 and those with 
measurements ≥ 3.5 and compared the significant of difference in the biomarkers in each 
group. Non-parametric bivariate correlation analysis was used to examine the 
association between biomarkers in pregnancies with congenital cardiac defects and 
those with normal cardiac anatomy. 
For the second and third trimester the observed measurements of fetal HC, AC and FL 
were expressed as the respective Z-score corrected for gestational age. UtA-PI was 
analyzed as described for the first trimester. 
For the third trimester, UA-PI and MCA-PI were log10 transformed to make their 
distributions Gaussian and each value was expressed as a multiple of the normal median 
(MoM) after adjustment for those characteristics that provide a substantial contribution 
to the log10 transformed value. 
The statistical software package SPSS 22.0 (IBM SPSS Statistics for Windows, Version 
22.0. Armonk, NY: IBM Corp, 2013) was used for the data analyses. 
 
4.4  Classification of cardiac defects: first and second trimester 
 
Major cardiac defects were subdivided into three groups based on the previous 
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publication from Llurba et al. (Llurba et al., 2013): 
1) Conotruncal defects: tetralogy of Fallot (TOF), transposition of great arteries (TGA), 
double outlet right ventricle (DORV), and common arterial trunk.  
2) Left ventricular outflow tract (LVOT) defects: hypoplastic left heart syndrome 
(HLHS), aortic stenosis (AS), coarctation of aorta (CoA), and interrupted aortic arch.  
3) Valvular defects: atrioventricular septal defects (AVSD), tricuspid stenosis or atresia 
(TS or TA), pulmonary stenosis or atresia (PS or PA), and Ebstein’s anomaly. 
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CHAPTER 5 RESULTS 
 
 
5.1 First trimester 
 
5.1.1 Maternal and pregnancy characteristics 
 
The 50,094 singleton pregnancies fulfilling the entry criteria included 49,898 pregnancies 
with a normal cardiac anatomy and 196 (0.4%) with major congenital cardiac defects. Of 
those, 73 (37.2%) were with conotruncal defects, 63 (32.1%) with LVOT defects and 60 
(30.6%) with valvular abnormalities, respectively. The maternal and pregnancy 
characteristics are represented in Table 5.1. 
 
Table. 5.1 Demographic and pregnancy characteristics in fetuses with congenital heart defects, 
stratified according to sub-groups, compared to those with normal cardiac anatomy. 
Maternal characteristics No cardiac defect (n=49,898) 
All cardiac defects 
(n=196) 
Age, median (IQR) 31.2  (26.7-34.8) 
31.7  
(26.1-36.1) 
Weight, median (IQR) 66.9  (59.1-77.7) 
67.0  
(58.5-78.9) 
Height, median (IQR) 1.65  (1.60-1.69) 
1.65  
(1.59-1.70) 
Racial origin   
     Caucasian, n (%) 36,327 (72.8) 146  (74.5) 
     Afro-Caribbean, n (%) 8,823 (17.7) 33  (16.8) 
     South Asian, n (%) 2,296  (4.6) 
9  
(4.6) 
     East Asian, n (%) 1,123  (2.3) 
5  
(2.6) 
     Mixed, n (%) 1,329  (2.7) 
3  
(1.5) 
Method of conception   
     Spontaneous, n (%) 48,317 (96.8) 189  (96.4) 
     Assisted conception, n (%) 1,581  (3.2) 
7  
(3.6) 
Cigarette smoking, n (%) 4,595  (9.2) 
16  
(8.2) 
Chronic hypertension, n (%) 735  (1.5) 
2  
(1.0) 
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SLE / APS, n (%) 114  (0.2) 0 
Diabetes mellitus, n (%) 435  (0.9) 
5  
(2.6) * 
Nulliparous, n (%) 25,003 (50.1) 101  (51.5) 
Inter-pregnancy interval, median (IQR) 3.0  (2.0-4.9) 
2.8  
(1.8-3.9) 
Post hoc Bonferroni correction for multiple comparisons; * = p< 0.0167; LVOT = left ventricular 
outflow tract; IQR = interquartile range; SLE = systemic lupus erythematosus; APS = 
antiphospholipid syndrome. 
 
 
5.1.2 Biomarkers in outcome groups 
 
In the cardiac defect group, compared to the normal cardiac anatomy group, the median 
PlGF MoM and PAPP-A MoM were lower, fetal delta NT was higher and UT-PI MoM was 
not significantly different. In all the sub-groups of congenital cardiac defects, this trend 
was maintained with lower PLGF and PAPP-A MoMs, higher delta fetal NT but no 
significant difference in UT-PI MoM (Table 5.2, Figure 5.1). 
 
 
Table 5.2. First trimester median and interquartile range of biomarkers in fetuses with congenital 
cardiac defects compared to those with a normal cardiac anatomy. 
 
Marker 
No cardiac 
defect 
(n=49,898) 
All cardiac 
defects 
(n=196) 
Conotruncal 
defects 
(n=73) 
LVOT 
defects 
(n=63) 
Valvular 
defects 
(n=60) 
Serum PAPP-A 
MoM 
1.00  
(0.69-1.42) 
0.81  
(0.52-1.27)** 
0.73  
(0.57-1.18)* 
0.73  
(0.44-1.29)* 
0.90  
(0.55-1.32) 
Serum PlGF 
MoM 
1.00  
(0.77-1.29) 
0.78  
(0.56-1.07)** 
0.75  
(0.55-0.97)** 
0.80  
(0.56-1.19)* 
0.74  
(0.61-1.17)* 
UTPI MoM 1.00  (0.81-1.22) 
1.01  
(0.83-1.26) 
0.97  
(0.81-1.28) 
1.05  
(0.84-1.29) 
1.00  
(0.89-1.25) 
Delta fetal NT 0.00  (-0.20-0.22) 
0.28  
(-0.06-0.86)** 
0.19  
(-0.11-0.68)** 
0.47  
(-0.02-0.89)** 
0.24  
(-0.04-0.96)** 
Significance value *p<0.01; **p<0.001; post hoc Bonferroni correction for multiple comparisons; 
LVOT = Left ventricular outflow tract; PAPP-A = pregnancy associated plasma protein-A;  PLGF 
= placental growth factor; UTPI = uterine artery pulsatility index ; NT = nuchal translusency; MoM 
= Multiple of normal median. 
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Figure 5.1 First trimester maternal serum placental growth factor in pregnancies with major 
congenital cardiac defects compared to those without defects and for each group of cardiac 
defects. The cardiac defect group is subdivided according to high or normal NT and 
according to type of defect. 
 
 
 
LVOT, left ventricular outflow tract 
 
 
A significant association between PlGF MoM and delta fetal NT was found in the group 
with cardiac defects but not in those without defects (Table 5.3). In fetuses with cardiac 
defects and increased NT PlGF MoM was significantly lower in those with increased NT, 
compared to those with normal NT (0.56 vs 0.83 MoM; p=0.007) (Figure 5.2); there was 
no significant difference in PAPP-A MoM between the two groups (0.84 vs 0.79 MoM; 
p=0.586). 
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Table 5.3 First trimester correlations between biophysical and biochemical markers in fetuses 
with and without congenital cardiac defects.  
Marker 
Congenital cardiac defects 
Serum PlGF 
MoM 
Serum PAPP-A 
MoM 
Uterine artery PI 
MoM Delta fetal NT 
Serum PlGF 
MoM - 
r = 0.34; 
p<0.0001 
r = -0.23;  
p = 0.001 
r = -0.15;  
p = 0.03 
Serum PAPP-A 
MoM  - 
r = -0.22;  
p = 0.002 
r = -0.010;  
p = 0.9 
Uterine artery PI 
MoM   - 
r = -0.08;  
p = 0.3 
Delta fetal NT    - 
 
Normal cardiac anatomy 
Serum PlGF 
MoM 
Serum PAPP-A 
MoM 
Uterine artery PI 
MoM Delta fetal NT 
Serum PlGF 
MoM - 
r = 0.29; 
p<0.0001 
r = -0.13; 
p<0.0001 
r = 0.004;  
p = 0.4 
Serum PAPP-A 
MoM  - 
r = -0.15; 
p<0.0001 
r = 0.02;  
p <0.0001 
Uterine artery PI 
MoM   - 
r = -0.006;  
p = 0.2 
Delta fetal NT    - 
PAPP-A = pregnancy associated plasma protein-A;  PLGF = placental growth factor; UTPI = uterine artery 
pulsatility index ; NT = nuchal translusency; MoM = Multiple of normal median. 
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5.2  Second trimester 
 
5.2.1  Maternal and pregnancy characteristic 
 
The 93,408 singleton pregnancies fulfilling the entry criteria included 92,779 pregnancies 
with a normal cardiac anatomy and 629 (0.7%) with major congenital cardiac defects. 
The maternal and pregnancy characteristics in the outcome groups are represented in 
Table 5.4. 
 
Table 5.4 Second trimester maternal and pregnancy characteristics in fetuses with 
congenital cardiac defect compared to those with normal cardiac anatomy 
Maternal characteristics No cardiac defect (n=92,779) 
All cardiac defects 
(n=629) 
Age, median (IQR) 30.9 (26.3-34.9) 31.0 (26.0-35.3) 
Weight, median (IQR) 67.0 (56.9-77.6) 64.0 (59.1-72.2) 
Height, median (IQR) 164.0 (160.0-168.5) 165.0 (160.0-167.74) 
Racial origin   
     Caucasian, n (%) 65837 (71.0) 489 (77.7) 
     Afro-Caribbean, n (%) 17059 (18.4) 74 (11.8) ** 
     South Asian, n (%) 5093 (5.5) 47 (7.5) * 
     East Asian, n (%) 2583 (2.8) 8 (1.3) 
     Mixed, n (%) 2207 (2.4) 11 (1.7) 
Method of conception   
     Spontaneous, n (%) 90593 (97.6) 611 (97.1) 
     Assisted conception, n (%) 2186 (2.4) 18 (2.9) 
Cigarette smoking, n (%) 9456 (10.2) 64 (10.2) 
Chronic hypertension, n (%) 1207 (1.3) 1 (0.2) * 
SLE / APS, n (%) 179 (0.2) 1 (0.2) 
Diabetes mellitus, n (%) 859 (0.9) 6 (1.0) 
Nulliparous, n (%) 46294 (49.9) 286 (45.5) 
Inter-pregnancy interval, median (IQR) 2.8 (1.8-4.7) 3.0 (2.6-3.4) 
      Post hoc Bonferroni correction for multiple comparisons; * = p < 0.05; ** = p < 0.001; IQR = 
interquartile range; SLE = systemic lupus erythematosus; APS = antiphospholipid syndrome. 
 
Overall, the incidence of CHDs was significantly higher in Afro-Caribbean and South 
Asian ethnic groups compared with controls (11.8% and 7.5%, p<0.001 and p<0.005, 
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respectively). In women with chronic hypertension there was a lower incidence of CHD 
compared to control (1.0% vs 0.9%, p<0.05).  
 
5.2.2  Fetal biometry and UtA Doppler in all CHDs compared to control group 
 
Results for fetal biometry are shown in Table 5.5 and Figure 5.2. The calculated Z-score 
for HC, AC and FL measurements in pregnancies with CHD is compared to controls: Z-
scores of HC, AC and FL were significantly lower than controls (-0.26, -0.16 and -0.26, 
respectively, p < 0.001) while there was no difference in UtA-PI between the two groups 
(1.00 vs 1.03). 
 
Table 5.5 Second trimester calculated z-score for head circumference, abdominal circumference 
and femur length, in fetuses with congenital heart defects compared to those with normal cardiac 
anatomy. 
Marker No cardiac defect (n=92,779) 
All cardiac defects 
(n=629) 
Head circumference z-score 0.00 (-0.46 – 0.47) -0.26 (-0.92 – 0.30)** 
Abdominal circumference z-score 0.00 (-0.43 – 0.42) -0.16 (-0.66 – 0.42)** 
Femur length z-score 0.00 (-0.45 – 0.46) -0.26 (-0.87 – 0.25)** 
Uterine artery PI MoM 1.00 (0.84 – 1.20) 1.03 (0.87 – 1.31) 
Significance value * p<0.01; ** p<0.001; post hoc Bonferroni correction for multiple 
comparisons 
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Figure 5.2 Second trimester box-and-whisker plots of Z-scores for fetal head circumference (a), 
abdominal circumference (b), femur length (c) and uterine artery pulsatility index (d) in fetuses 
with congenital heart defects compared to those with normal cardiac anatomy. Boxes with 
interlines represent median and interquartile range and whiskers are range.   
 
CHD, congenital heart defects 
 
 
5.2.3  Fetal biometry and UtA Doppler in CHD, divided by sub-groups and 
compared to controls 
 
Table 5.6 shows the Z-scores for HC, AC and FL measurements in pregnancies with 
CHD, divided in three sub-groups and compared to control group: HC and FL were 
significantly smaller in all subgroups of CHDs (p < 0.001); significantly lower values for 
AC Z-score were found in LVOT defects and, though a trend towards lower Z-score 
values was observed also for conotruncal and valvular defects, the difference did not 
reach a statistical significance. Same results are shown in Figure 5.4, Figure 5.5 and 
Figure 5.6 with the box-and-whiskers plot graphs for HC, AC and FL Z-score, 
respectively.  
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Table 5.6 Second trimester median and interquartilie range of fetal biometric parameter in fetuses 
with congenital cardiac defects, stratified according to sub-groups, compared to those with a 
normal cardiac anatomy. 
Marker 
No cardiac 
defect 
(n=92,779) 
Conotruncal 
defects 
(n=269) 
LVOT defects 
(n=225) 
Valvular 
defects 
(n=135) 
Head circumference z-
score 
0.00  
(-0.46 – 0.47) 
-0.29  
(-0.98 – 
0.20)** 
-0.15  
(-0.84 – 0.44)** 
-0.39  
(-0.87 – 0.30)** 
Abdominal circumference 
z-score 
0.00  
(-0.43 – 0.42) 
-0.14  
(-0.69 – 0.45) 
-0.22  
(-0.68 – 0.29)** 
-0.08  
(-0.63 – 0.61) 
Femur length z-score 0.00  (-0.45 – 0.46) 
-0.24  
(-0.83 – 
0.33)** 
-0.26  
(-0.93 – 0.22)** 
-0.32  
(-0.83 – 0.33)** 
Significance value * p<0.01; ** p<0.001; post hoc Bonferroni correction for multiple comparisons; 
LVOT = Left ventricular outflow tract 
 
 
 
Fig. 5.4 Second trimester Box-and-whisker plots of Z-scores for head circumference (HC) in 
fetuses with congenital heart defects, stratified according to sub-groups, compared to those with 
normal cardiac anatomy. Boxes with interlines represent median and interquartile range and 
whiskers are range.   
 
                       LVOT, left ventricular outflow 
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Fig. 5.5 Second trimester box-and-whisker plots of Z-scores for abdominal circumference (AC) 
in fetuses with congenital heart defects, stratified according to sub-groups, compared to those 
with normal cardiac anatomy. Boxes with interlines represent median and interquartile range 
and whiskers are range.   
 
                 LVOT, left ventricular outflow 
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Fig. 5.6 Second trimester box-and-whisker plots of Z-scores for femur length (FL) in fetuses with 
congenital heart defects, stratified according to sub-groups, compared to those with normal 
cardiac anatomy. Boxes with interlines represent median and interquartile range and whiskers 
are range.   
 
 
                 LVOT, left ventricular outflow 
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5.3 Third trimester 
 
5.3.1 Maternal and pregnancy characteristics 
 
The 47,884 singleton pregnancies fulfilling the entry criteria included 47,716 pregnancies 
with a normal cardiac anatomy and 168 (0.35%) with major congenital cardiac defects. 
The maternal and pregnancy characteristics in the outcome groups are represented in 
Table 5.7. An increased incidence of CHD was observed in women with a lower weight 
than in the control group (p < 0.001). 
 
Table 5.7 Third trimester maternal and pregnancy characteristics in fetuses with congenital 
cardiac defect compared to those with normal cardiac anatomy 
Maternal characteristics No cardiac defect (n=47,716) 
All cardiac defects 
(n=168) 
Age, median (IQR) 31.3 (26.7 – 35.1) 30.5 (24.7 – 35.0) 
Weight, median (IQR) 76.6 (68.5 – 87.0) 65.0 (60.1 – 77.8)** 
Height, median (IQR) 164 (160 – 169) 165 (160 – 170) 
Racial origin   
     Caucasian, n (%) 33,725 (70.7) 127 (75.6) 
     Afro-Caribbean, n (%) 8,935 (18.7) 25 (14.9) 
     South Asian, n (%) 2,527 (5.3) 11 (6.5) 
     East Asian, n (%) 1,290 (2.7) 1 (0.6) 
     Mixed, n (%) 1,239 (2.6) 4 (2.4) 
Method of conception   
     Spontaneous, n (%) 46,124 (96.7) 161 (95.8) 
     Assisted conception, n (%) 1,592 (3.3) 7 (4.2) 
Cigarette smoking, n (%) 4,432 (9.3) 16 (9.5) 
Chronic hypertension, n (%) 666 (1.4) 0 
SLE / APS, n (%) 119 (0.2) 1 (0.6) 
Diabetes mellitus, n (%) 465 (1.0) 0  
Nulliparous, n (%) 23,305 (48.8) 82 (48.8) 
Inter-pregnancy interval, median (IQR) 2.9 (1.9 – 4.8) 3.0 (2.9 – 3.0) 
Post hoc Bonferroni correction for multiple comparisons; ** = p < 0.001; IQR = interquartile range; 
SLE = systemic lupus erythematosus; APS = antiphospholipid syndrome. 
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5.3.2  Fetal biometry and fetal-maternal Doppler in CHD compared to control 
group 
 
Results for fetal biometry and fetal-maternal Doppler parameters are shown in Table 5.8, 
Figure 5.7 and Figure 5.8. Overall, the calculated Z-scores for HC, AC and FL 
measurements in pregnancies with CHD were significantly lower than in control group (p 
< 0.001).  UtA-PI and UA-PI were significantly higher in fetuses with CHD than in control 
group (p < 0.01 and p < 0.001, respectively) while there was no difference in MCA-PI 
between the two groups (1.01 vs 1.02). 
 
Table 5.8 Third trimester median and interquartilie range of biomarkers in fetuses with congenital 
cardiac defects compared to those with a normal cardiac anatomy 
Marker No cardiac defect (n=47,716) 
All cardiac defects 
(n=168) 
Head circumference z-score 0.00 (-0.41 – 0.44) -0.18 (-0.70 – 0.39)** 
Abdominal circumference z-score 0.00 (-0.40 – 0.41) -0.26 (-0.87 – 0.35)** 
Femur length z-score 0.00 (-0.45 – 0.46) -0.53 (-1.27 – 0.22)** 
Uterine artery PI MoM 1.00 (0.85 – 1.19) 1.05 (0.89 – 1.37)* 
Umbilical artery PI MoM 1.01 (0.91 – 1.13) 1.11 (0.96 – 1.27)** 
Middle cerebral artery PI MoM 1.01 (0.90 – 1.12) 1.02 (0.84 – 1.14) 
Significance value * p<0.01; ** p<0.001; post hoc Bonferroni correction for multiple comparisons; 
MoM = Multiple of the Median 
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Figure 5.7 Third trimester box-and-whisker plots of Z-scores for fetal head circumference (a), 
abdominal circumference (b), femur length (c) in fetuses with congenital heart defects compared 
to those with normal cardiac anatomy. Boxes with interlines represent median and interquartile 
range and whiskers are range.   
 
 
 
CHD, congenital heart defects 
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Figure 5.8 Third trimester box-and-whisker plots of Z-scores for umbilical artery pulsatility index 
(a), middle cerebral artery pulsatility index (b) in fetuses with congenital heart defects compared 
to those with normal cardiac anatomy. Boxes with interlines represent median and interquartile 
range and whiskers are range.   
 
 
CHD, congenital heart defects 
 
 
5.3.3  Fetal biometry and fetal-maternal Doppler in CHD, divided by sub-groups, 
compared to control group 
 
Table 5.9 shows the Z-scores for HC, AC and FL measurements in pregnancies with 
CHD, divided in the three sub-groups, and compared to control group:  
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The HC was significantly smaller just in LVOT subgroup but not in valvular and 
conotruncal defects; AC was significantly smaller in LVOT and valvular defect but not in 
conotruncal, respectively; FL was significantly smaller in all CHD subgroups (p < 0.0167). 
For Doppler parameters, UA-PI was significantly higher in all CHD subgroups, while 
MCA-PI was significantly reduced just in LVOT defects subgroup. There were no 
differences in UtA-PI among the study groups.   
 
Table 5.9 Third trimester median and interquartile range of biomarkers and Doppler parameters 
in fetuses with congenital cardiac defects, stratified according to sub-groups and compared to 
those with a normal cardiac anatomy. 
Marker 
No cardiac 
defect 
(n=47,716) 
Conotruncal 
defects 
(n=62) 
LVOT defects 
(n=48) 
Valvular 
defects 
(n=58) 
Head circumference z-
score 
0.00 (-0.41 – 
0.44) 
-0.22 (-0.76 – 
0.52) 
-0.32 (-0.66 – 
0.28)* 
0.03 (-0.61 – 
0.31) 
Abdominal 
circumference z-score 
0.00 (-0.40 – 
0.41) 
-0.29 (-0.79 – 
0.30) 
-0.74 (-1.15 – 
0.14)* 
-0.38 (-1.06 – 
0.14)* 
Femur length z-score 0.00 (-0.45 – 0.46) 
-0.49 (-1.01 – 
0.15)* 
-0.61 (-1.64 – 
0.23)* 
-0.56 (-1.30 – 
0.52)* 
Uterine artery PI MoM 1.00 (0.85 – 1.19) 
1.12 (0.93 – 
1.50) 
0.99 (0.90 – 
1.50) 
1.01 (0.85 – 
1.28) 
Umbilical artery PI MoM 1.01 (0.91 – 1.13) 
1.05 (0.94 – 
1.27)* 
1.14 (0.95 – 
1.29)* 
1.13 (0.99 – 
1.24)* 
Middle cerebral artery 
PI MoM 
1.01 (0.90 – 
1.12) 
1.06 (0.84 – 
1.15)  
0.90 (0.80 – 
1.04)* 
1.07 (0.91 – 
1.20) 
Significance value * p<0.0167; post hoc Bonferroni correction for multiple comparisons;  
LVOT = Left ventricular outflow tract; PI = pulsatility index; MoM = Multiple of normal median. 
 
Same results are shown in Figure 5.9, Figure 5.10, Figure 5.11, Figure 5.12 and Figure 
5.13 with the box-and-whiskers plot graphs for HC, AC, FL, UA-PI and MCA-PI Z-score, 
respectively.  
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Figure 5.9 Third trimester box-and-whisker plots of Z-scores for head circumference in fetuses 
with congenital heart defects, stratified according to sub-groups, compared to those with normal 
cardiac anatomy. Boxes with interlines represent median and interquartile range and whiskers 
are range.   
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Figure 5.10 Third trimester box-and-whisker plots of Z-scores for abdominal circumference in 
fetuses with congenital heart defects, stratified according to sub-groups, compared to those 
with normal cardiac anatomy. Boxes with interlines represent median and interquartile range 
and whiskers are range.   
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Figure 5.11 Third trimester box-and-whisker plots of Z-scores for femur length in fetuses with 
congenital heart defects, stratified according to sub-groups, compared to those with normal 
cardiac anatomy. Boxes with interlines represent median and interquartile range and whiskers 
are range.   
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Fig. 5.12 Third trimester Box-and-whisker plots of Z-scores for umbilical artery pulsatility index in 
fetuses with congenital heart defects, stratified according to sub-groups, compared to those with 
normal cardiac anatomy. Boxes with interlines represent median and interquartile range and 
whiskers are range.   
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Fig. 5.13 Third trimester box-and-whisker plots of Z-scores for middle cerebral artery pulsatility 
index in fetuses with congenital heart defects, stratified according to sub-groups, compared to 
those with normal cardiac anatomy. Boxes with interlines represent median and interquartile 
range and whiskers are range.   
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CHAPTER 6 DISCUSSION 
 
Principal findings of the study:  in fetuses with CHDs there is a placental dysfunction, 
supported by lower concentration of maternal serum PlGF and PAPP-a, in the presence 
of normal uterine perfusion. In the second trimester, all components of fetal growth are 
affected in the presence of normal placental perfusion. In the third trimester, again, fetal 
growth is overall affected with no difference in MCA-PI while the presence of placental 
dysfunction is reflected by increased resistance in the UA and UtA-PI Doppler 
velocimetry. 
 
6.1 First trimester 
 
Previous investigation from Llurba et al., have raised the hypothesis that in pregnancies 
where the fetus carries an isolated major cardiac defect there are signs of placental 
dysfunction in the presence of a normal uterine perfusion in certain types of cardiac 
defects (Llurba et al., 2013). We wanted to verify this hypothesis on a larger population 
sample keeping the same classification of cardiac defects described by Llurba et al. 
 
6.1.1 Placental factors 
The main result in our population of fetuses with CHD, within the first trimester of 
pregnancy, is the evidence of a primary placental dysfunction.  
The results obtained in our population are significantly different from the first study from 
Llurba et al in many aspects (Table 6.1). In the study from Llurba et al, while PlGF was 
significantly reduced in all pregnancies with CHD, PAPP-a was not (Llurba et al, 2013). 
Furthermore, subanalysis by heart defect subgroups showed that this was true for 
valvular and conotruncal abnormalities but not for LVOT. Different reasons were 
advocated to explain these findings, and one was the possible multifactorial 
pathogenesis of such defects. In this population, we substantially increased the number 
of cases analyzed for each subgroup and, particularly so, for LVOT defects: we had 63 
cases compared to 11 included from Llurba et al. Therefore, it seems reasonable to 
conclude that pregnancies with CHD are characterized by lower concentrations of PlGF 
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in maternal serum, regardless of the type of cardiac defect. Similarly, PAPP-a showed a 
significant reduction in all CHD subgroups. 
 
Table 6.1 Comparisons between the results reported by Llurba et al and results of our population 
Llurba et al 2013 
 
Fantasia et al 2016 
 
LVOT 11 LVOT 63 
Conotruncal 25 Conotruncal 73 
Valvar  35 Valvar  60 
All CHDs 
 
All CHDs 
 
reduced PlGF MoM p < 0.001 reduced PlGF MoM p < 0.001 
increased dNT p < 0.001 increased dNT p < 0.001 
PAPP-a NS PAPP-a p < 0.001 
UtA-PI NS UtA-PI p < 0.001 
PlGF in CHD 
subgroups:  
 
PlGF in CHD 
subgroups:  
 
Valvar  p < 0.001 Valvar  p < 0.001 
Conotruncal p < 0.001 Conotruncal p < 0.001 
LVOT ns LVOT p < 0.001 
Log10PlGF-MoM 
and dNT: 
 
Log10PlGF-MoM and 
dNT: 
 
all CHD p < 0.0001 all CHD p < 0.0001 
controls ns controls ns 
dNT in all CHD and 
PlGF: 
 
dNT in all CHD and 
PlGF: 
 
abnormal NT p < 0.0001 abnormal NT p < 0.0001 
normal NT ns normal NT p < 0.0001 
LVOT, left ventricular heart defects; CHD, congenital heart defects, PlGF, placental growth factor; 
NT, nuchal translucency; dNT, delta nuchal translucency; NS, not significant. 
 
Both PAPP-a and PlGF are markers of impaired placental function in pregnancies at risk 
of developing adverse obstetrical outcomes, like preeclampsia and IUGR (Poon and 
Nicolaides, 2014). However, in these cases, the physiological process of remodeling of 
the spiral arteries is inadequate resulting in high resistance in the UtA. Since blood 
perfusion on maternal side is defective, certain degree of placental insufficiency is 
established causing lower concentrations of placenta-related factors, such as PlGF and 
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PAPP-A, in maternal blood (Akolekar et al, 2008). 
 
We showed, on a large population sample, that in fetuses with CHDs signs of placental 
dysfunction are present, as confirmed by lower concentrations of PLGF and PAPP-a, but 
the utero-placental perfusion on maternal side is normal, as confirmed by normal values 
of Ut-PI. This would suggest that these pregnancies are characterized by a primary 
placental dysfunction. 
 
6.1.2 Environmental factors 
The importance of environmental factor on the etiology of CHDs is supported by the 
analysis of maternal characteristics in our population:  the presence of diabetes mellitus 
was significantly associated with the presence of CHD suggesting that hyperglycemia 
during early embryogenesis may alter gene expression in key cellular components of the 
developing heart. However, the mechanism producing this altered gene expression is 
still unclear (Kumar et al, 2007; Morgan et al, 2008).   
 
Chronic hypertension and smoking were not significantly associated with any subgroup 
of CHDs and neither was the method of conception. While, indeed, the first two are not 
associated to CHDs, there is some evidence to support that pregnancies conceived 
through assisted reproductive techniques (ART) have an increased risk of fetal CHDs 
(REF). The American Heart Association (AHA) considers in-vitro fertilization (IVF), and 
mainly intracytoplasmatic sperm injection (ICSI), as an indication for a detailed cardiac 
scan with recommendation class/level of evidence of IIa/A and an absolute risk of 1.1-
3.3% among live births (Donofrio et al, 2014). The risk for CHDs seems to be higher in 
pregnancies conceived with IVF/ICSI techniques rather than ovulation induction (Tararbit 
et al, 2013). In a recent meta-analysis on the incidence of CHDs in pregnancies 
conceived through IVF/ICSI, the odd ratio (OR) for CHDs was higher in the IVF/ICSI 
group than in naturally conceived infants (OR 1.55; 95% CI 1.21–1.99; p=0.18) 
(Giorgione et al, 2017). Quite interestingly, an association between pregnancies 
conceived by IVF techniques and low maternal serum concentrations of PAPP-a has 
been reported by different authors (Tul et al., 2006; Amor et al., 2009), suggesting a 
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causative relationship between IVF/ICSI technique, low PAPP-a and CHDs. However, 
no studies investigated this aspect on IVF pregnancies.  In our cohort the total number 
of IVF pregnancies compared to the spontaneous (7 vs 189, respectively) was too little 
to perform a comparison between the two groups. Nonetheless, the findings that 
pregnancies carrying a fetus with CHD are characterized by lower levels of PAPP-a and 
that this factor could be someway responsible or linked to the increased incidence of 
heart defects in IVF pregnancies, open the possibility of new fields of investigation on 
this specific topic.  
 
6.1.3 Nuchal translucency 
In pregnancies with major cardiac defects fetal NT is increased, and in those with high 
NT serum PlGF is lower than in those with normal NT, while there were no significant 
differences in PAPP-a between the two groups. We also confirmed these results finding 
a significant inverse correlation between NT and PlGF for each subgroup of CHD and no 
association with PAPP-a. These results confirm, on a larger sample, what has been 
already found by Llurba et al., who hypothesized a common pathophysiological 
mechanism for high NT and low PLGF but not for PAPP-a (Llurba et al., 2013). PlGF, as 
part of the family of VEGF, may act on the same routes described for VEGF that are 
essential for the development of normal lymphatic vessels (Shibuya et al, 2008). 
Therefore, these data suggest that there might be a relation between PlGF and increased 
NT however, the etiology is still unknown. 
 
6.2 Second trimester 
 
Previous investigations have reported that fetuses with CHDs are at risk of being small 
for gestational age at birth (Marino et al., 2012; Matthiesen et al., 2016). We wanted to 
verify if the presence of placental dysfunction, reported in the first trimester, have an 
impact on second trimester fetal growth. 
 
6.2.1 Fetal growth restriction 
Results from the analysis in the second trimester show that in fetuses with CHDs all 
components of fetal biometry are significantly affected when compared to controls. 
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Further analysis by subgroups show that, while HC and FL are significantly smaller in all 
three subgroups, AC is significantly affected just in LVOT defects. A negative trend was 
observed also for valvar and conotruncal defects, though the difference was not 
significant. Uterine arteries perfusion is normal as shown by normal values of UtA-PI in 
fetuses with CHD as in controls. 
 
The association between the presence of various types of congenital malformations and 
fetal growth restriction (FGR) is well known (Sarkar et al., 2013; Raynor et al.,1997). In 
fetuses with CHDs, the question if fetal systemic hemodynamic changes have an impact 
on fetal growth, secondarily to the cardiac abnormality, has arisen. Specifically, the link 
between low birthweight in CHDs and poor neurodevelopmental outcomes (Walden et 
al., 2007), led different authors to investigate on the sole HC as a prenatal marker of 
NDD assuming that if brain perfusion is impaired, because of the cardiac abnormality, 
also brain growth would have been affected with smaller prenatal HC (Williams et al., 
2015; Masoller et al., 2014; Turan et al., 2016; Ruiz et al., 2016; Haveman et al., 2018; 
Hahn et al., 2016; Jansen et al., 2016). Few studies considered AC and FL in their 
analysis and results are contradictory: if they all agreed that HC was smaller than 
controls, lower values of AC and FL were reported in some of them (Jansen et al. 2016; 
Turan et al. 2016; Williams et al, 2015) but not in others (Masoller et al. 2014, Ruiz et al. 
2016). 
 
The question, here, that need to be answered is: is it just the head that is smaller because 
of an impaired blood flow to the brain or the whole components of fetal growth are 
affected because of some elements of placental dysfunction? 
 
In our study, done on a large population sample, we found that these fetuses are 
characterized by a symmetric fetal growth restriction, which is supported by the findings 
of Turan et al. and Williams et al., where the calculation of the HC/AC ratio did not identify 
body asymmetry in any of the cardiac abnormality groups (Williams et al., 2015, Turan 
et al., 2016).  
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In Table 6.2, our results are compared with those studies that reported Z-score for, at 
least, HC and AC. It is clear that a negative trend is present for HC and FL, with small 
deviations from median values, as for our results. AC seems to be less affected in the 
study of Masoller et al. and Ruiz et al., but significance is obtained when bigger numbers 
are included in the analysis as for Jansen et al. and our study. No studies reported the 
presence of true macrocephaly, defined as a HC < -3SD, or severe fetal growth 
restriction, defined as AC or EFW < 3rd centile, and the clinical relevance of the decrease 
in fetal size is overall small. 
 
Table 6.2 Comparison between our results and other studies reporting Z-score for HC, AC and 
FL in the second trimester of pregnancy. 
 
 Masoller et al, 
2014 
Ruiz et al, 
2016 
Jansen et al,  
2016 
Our results 
Total N 
CHDs 
95 119 343 629 
HC Z-score -0.89 ± 1.43 -0.79 ± 1.02 -0.06 (-0.18-0.06) -0,26 (-0.92 – 0.30) 
AC Z-score  0.27 ± 0.79  0.49 ± 0.88 -0.05 (-0.15-0.06) -0,16 (-0.66 – 0.42) 
FL Z-score -0.09 ± 1.26 -0.04 ± 0.49 NR -0,26 (-0.87 – 0.25) 
HC, head circumference; AC, abdominal circumference; FL, femur length; NR, not reported 
 
The finding of a small deviation from median biometric values in newborns with CHDs is 
also supported by the largest series on a Danish population of 924422 newborns, 
including 5519 babies with different types of CHDs, showing that the mean z-score 
difference in birthweight between all infants with CHD and the general population was –
0.10 (95% confidence interval [CI], –0.13 to –0.08) and that, overall, birthweight z-score 
was modestly smaller than HC resulting in symmetrically small infants (Matthiensen et 
al., 2016).  
 
6.2.2 Placental factors 
In our population, the presence of FGR happens in the presence of a normal uterine 
perfusion as supported by normal values of UtA-PI that imply a normal trophoblastic 
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arrangement in the first trimester. There is just one study, from Ruiz et al., that included 
the assessment of the UtA-PI in the second trimester of pregnancy and they found that, 
despite the smaller biometry, UtA-PI was within normal ranges supporting the hypothesis 
that fetal smallness in the presence of a CHD is not related to abnormal uterine perfusion. 
Data on placental histology identified a specific pattern of lesion, called fetal thrombotic 
vasculopathy (FTV), characterized by regionally distributed avascular villi and often 
accompanied by upstream thrombosis in placental fetal vessels. Saleemuddin et al., 
reported a 6-fold increased risk of fetal cardiac abnormalities, including ventricular or 
atrial septal defects, tetralogy of Fallot, aortic coarctation, double outflow tract, 
cardiomegaly, dextrocardia, and aortic stenosis, and a 2-fold increased risk of 
intrauterine growth restriction, when FVT was reported (Saleemuddin et al., 2010). It is 
quite difficult to identify specific clusters of placental abnormalities related to defined fetal 
or maternal conditions because different maternal risk factors, like obesity and 
preeclampsia, frequently coexist in the same pregnancy (Stanek et al., 2012). However, 
some histological findings are more specific than others for some conditions: for 
example, placenta of pregnancies affected by preeclampsia are usually smaller and 
characterized by the presence of chorionic villi defined “hypermature” for gestational age 
with aspects resembling those of a later gestational age, while placenta from women with 
diabetes can be larger or smaller with signs of hypervascularization and chorangiosis 
(Tyson et al., 2008). Despite the few data exploring this aspect, there are some 
evidences to support the fact that the histological placental pattern of fetuses with CHDs 
is different from that of pregnancies with placental insufficiency secondary to uterine 
underperfusion that are, usually, characterized by more severe pattern of FGR. This 
might explain why fetal size is just moderately affected in fetuses with CHDs, but further 
studies are needed to investigate on the correlation between CHDs, FGR, placental 
histology and uterine perfusion.  
 
6.2.3 Environmental factors 
In the second trimester, there was a significantly higher number of CHDs in the group of 
women of Afro-Caribbean and South-Asian racial origin, while this was not the case in 
the first trimester. This might be due to the different numbers of CHDs included, which 
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was much higher in the second trimester than in the first (629 vs 196, respectively).  
Previous studies on the distribution of maternal biomarkers by ethnicity, showed that 
women of Afro-Caribbean and South-Asian ethnicity have higher maternal PlGF and 
PAPP-a serum concentrations (Tsiakkas et al., 2015), and this seems to contradict our 
results in the first trimester population. However, in a recent analysis on the incidence of 
CHDs by ethnicity in a population of 5350 infants born in United Kingdom (UK), the 
overall incidence of CHDs was significantly higher in Asian and Black ethnic groups 
compared to the Caucasian population. The analysis of these subgroups by regional 
areas highlighted that British non-White ethnic populations were more likely to be living 
in more socioeconomically deprived areas, therefore highlighting the importance of 
maternal environmental factors on the etiology of fetal CHD.  
 
Another finding emerging from the analysis, is that women with chronic hypertension 
have a lower incidence of CHDs compared to controls (0.2% vs 1.3%, p<0.05). A recent 
study on the incidence of preeclampsia in women with chronic hypertension found that 
maternal serum concentrations of PlGF and PAPP-a are higher in women with chronic 
hypertension (Panaitescu et al., 2017). However, a definitive explanation for this finding 
cannot be given.  
 
 
6.3 Third trimester 
There is some evidence that fetuses with CHDs have a smaller HC and peculiar patterns 
of MCA-PI depending on the type of cardiac defects (Donofrio et al., 2003; Berg et al., 
2009; Kaltman et al, 2005; Masoller et al; 2016; Ruiz et al 2016). We wanted to 
investigate fetal growth and fetal-maternal Dopplers in our population in all fetuses with 
CHDs and according by sub-groups.   
6.3.1 Fetal biometry and fetal-maternal Dopplers 
Our data show that in fetuses with CHDs, fetal biometry is overall significantly reduced 
with a moderate deviation from median values. Analysis by subgroups shows that HC is 
significantly smaller only in LVOT defects. AC is significantly smaller than controls in 
LVOT and valvar defects, while for FL significance is reached in all subgroups. A 
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tendency towards negative values was present also for the other components of fetal 
biometry, but the difference was not significant. Again, as for the second trimester, the 
degree of FGR is mild and follows a symmetrical pattern.  
The presence of moderately increased resistance in the UtA flow, not reported in the first 
and second trimester group, is a new finding. This is in line with the only study evaluating 
UtA-PI in fetuses with a major CHD from Ruiz et al.: while they found normal values of 
UtA-PI in the second trimester, they observed a quadratic increase for both UA-PI and 
UtA-PI in the third trimester (Ruiz et al., 2016). Based on these findings we may 
speculate that increased resistance in the uterine arteries are secondary to the presence 
of placental dysfunction and that such changes become evident only in the third trimester 
either because of worsen degrees of the primary defect or because of additional effects 
of placental aging. Placental histology and serial measurements of maternal biomarkers 
in the second and third trimester could be helpful in the understanding of such 
phenomenon. 
Our data show that also UA-PI is moderately increased in fetuses with CHDs compared 
to controls and most severe patterns, like absent or reversed flow, where never 
observed. Previous studies reporting on the UA flow pattern (Kaltman et al; Masoller et 
al, 2016; Turan et al, 2016) give contradictory results. Kaltman et al. found significantly 
higher UA-PI in right-sided lesion and in HLHS and left-sided lesions but not to a 
significant degree; Yamamoto et al., observed an increased UA-PI in all cardiac defects 
(Yamamoto et al., 2013); others did not find any difference in UA-PI in any of the CHDs 
analyzed (Masoller et al. 2016; Ruiz et al., 2016). In the article from Turan et al., CHDs 
were divided in 4 groups of CHDs: 1) TGA; 2) left-sided lesions with retrograde aortic 
flow; 3) left-sided lesions with anterograde aortic flow; 4) right-sided lesions. They found 
that UA-PI z-score was higher in those CHDs with retrograde aortic arch flow and in 
those with pulmonary obstruction (p < 0.001 and p = 0.03, respectively), while it was 
normal in Group 1 and 3 (Turan et al., 2016).  
Different mechanisms have been advocated to explain the presence of increased 
resistance in fetuses with CHDs: some, like Kaltman et al., have speculated that reverse 
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shunting through the ductus arterious to the obstructed arterial system was decreasing 
diastolic blood flow in the UA, thereby elevating UA-PI (Kaltman et al., 2005). Others 
either did not provide any explanation for the finding (Turan et al., 2016) or related it to 
the presence of placental abnormalities secondary to unknown genetic or epigenetic 
condition (Yamamoto et al., 2013). Our data strengthen the hypothesis that in fetuses 
with CHD there is a primary placental dysfunction responsible of increased resistance in 
the placental bed, supported by low levels of PlGF and PAPP-a in the first trimester and 
reduced intrauterine fetal growth in the second and third trimester.  
The analysis of MCA-PI showed that, overall, there was no difference between CHDs 
and controls. However, subanalysis by different subgroups showed that MCA-PI is 
significantly lower in fetuses with LVOT defects than in valvar and conotruncal which, 
instead, were characterized by higher levels of MCA-PI though the difference with 
controls was not significant.  
Stating first that, due to the heterogenicity between all studies in the clustering of cardiac 
defects included, a comparison between the findings have some limitations, we can see 
a tendency toward similar results: Masoller et al., in an interesting study on fetal biometry, 
Doppler ultrasound and functional MRI in fetuses with CHD identified two groups: group 
A with a low oxygen content and group B with a near-normal oxygen content and they 
found that MCA-PI Z-score was significantly lower in both groups (p<0.001) but Group A 
had a tendency towards lower values (Group A: –0.95 ± 0.95; Group B: –0.29 ± 1.14). 
Szwast et al compared single ventricle (SV) defects, divided in those with aortic 
obstruction and those with pulmonary obstruction: they found that MCA-PI Z-score was 
significantly lower in SV defects with aortic obstruction and significantly higher in SV 
defects in pulmonary obstruction (p<0.001) (Szwast et al., 2012). Autoregulation of the 
cerebral circulation to the blood flow directed to the brain was advocated as a possible 
explanation of these findings: a decrease in cerebrovascular resistance represents the 
brain’s attempt to increase blood flow in the face of an insufficient source of flow. 
Conversely, when a pulmonary obstruction is present, the vast majority of blood volume 
exits into an unobstructed aorta. The cerebral circulation therefore receives a 
substantially increased fraction of blood relative to normal, and autoregulates by 
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increasing cerebrovascular resistance in order to limit blood flow and prevent hyper-
perfusion. Again, similar findings were reported by Kaltman et al.  who found significantly 
higher MCA-PI Z-score in fetuses with HLHS than in fetuses with right-sided lesions, 
though in these defects the difference was not significant (Kaltman et al., 2005).  
There is, therefore, some evidence that the interpretation of fetal brain Doppler in the 
presence of a CHD should take into account the systemic fetal hemodynamics 
determined by each CHD and the principles applied to FGR fetuses should not be simply 
transferred to CHDs defects. Because of the different hemodynamic circumstances in 
CHDs versus growth restriction, conclusions should not be interchangeable. The 
presence of a major cardiac defect causes a subverted systemic circulation, that is not 
present in FGR fetuses, and that varies for each type of defect. The consequences of a 
possible reduced oxygenation on the MCA-PI pattern need to take into account also the 
impact of an altered systemic circulation and caution should be used in the inclusion of 
such findings as prognostic factors in the prenatal counseling. 
Moreover, studies that evaluated the correlation between fetal growth and post-natal 
neurodevelopmental outcome have found that there is a poor correlation between HC 
prenatal values and neurodevelopmental outcome. In their study, Williams et al. 
assessed the neurodevelopmental outcome of 18-months infants with CHDs (HLHS, 
TGA and TOF) by using the Bayleys Scales of Infant Development. They found that fetal 
biometry variables that correlated with Cognitive score included AC (r = 0.32, P = 0.049), 
HC/AC (r = -0.39, P = 0.02), and mean HC/AC (r = -0.4, P = 0.007) meaning that a larger 
abdominal relative to head circumference was associated with a higher score; language 
score correlated significantly with FL/BPD (r = 0.32, P = 0.037) and mean HC/AC (r = -
0.3, P = 0.045). They did not see any association between head size at any time in 
pregnancy, or in the neonatal period, and neurologic function (Williams et al., 2015). 
Similar findings were found by Hahn et al., in the analysis of both left and right single-
ventricle defects, where neither MCA-PI Z-score nor changes in MCA-PI Z-score, as 
gestation progressed, correlated with fetal HC Z-score or with post-natal 
neurodevelopmental outcome, while the only significant finding was that the mean of the 
individual fetal HC/AC ratios had a negative correlation with psychomotor developmental 
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outcome (r=−0.25, P=0.037; n=71) and as the HC/AC ratio decreased, PDI increased 
(Hahn et al., 2016).  
These findings highlight the importance of body symmetry for ultimate brain 
development, more so than the HC alone, and the lack of association may be because 
no true mechanistic relationship exists between fetal head growth and cerebral blood 
flow, with fetal head growth perhaps being influenced more by genetics, maternal factors 
such as nutrition and placental insufficiency, or other hemodynamic features not 
captured by repeated Doppler measures of the MCA-PI.  
6.4 Strength and limitations 
This study included a large population of pregnant women who attended for routine care 
in a gestational age range widely used for the assessment of the risk of chromosomal 
abnormalities. This allowed us to include a large number of patients whose fetus was 
affected by a major congenital heart defect, in order to systematically assess fetal 
biometry in relation to the uterine arteries perfusion in the second and third trimester of 
pregnancy. Furthermore, the study of the fetal anatomy was based on a specific protocol 
which included a detailed screening examination, review by fetal cardiologist in those 
with suspected abnormalities and neonatal examination by a pediatrician in all cases. 
Finally, a specific methodology was used by appropriately trained doctors to obtain 
measurements of fetal growth UtA-PI, UA-PI and MCA-PI. 
A limitation of the study is the absence of placental histology examination in order to 
identify, on a large scale, a specific pattern of the placental structure in fetuses with a 
CHD and to correlate it with the UtA flow. Moreover, we did not sample maternal serum 
PlGF in the second and third trimester in order to see its pattern also at later gestational 
ages and its possible relation to fetal growth.  
6.5 Future studies 
More studies are needed to answer the question of the pathogenic relationship between 
placental dysfunction and CHD. However, in the very first weeks of human gestation, 
investigating on placental function is difficult because of both ethical problems and 
unknow condition of the state of pregnancy in many cases. IVF pregnancies could be a 
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population eligible for an early assessment of placental function since pregnancy is 
diagnosed at a very early stage; moreover, the latest evidence that report an increased 
risk for CHD, made this population of particular interest in the field. 
Future research could try to add information to this aspect, for example, analyzing 
placental factors earlier in gestation or by studying not invasively placental volume by 3D 
acquisition images. Reus et al., have shown that the assessment of the trophoblast 
volume by using the three-dimensional (3D) ultrasound technique with Virtual Organ 
Computer-aided AnaLysis (VOCAL) can accurately assess placental volume from the 6th 
weeks of pregnancy and that smaller first-trimester trophoblast volume as well as 
reduced trophoblast growth were related to higher risk of miscarriage (Reus et al., 2013). 
Papastefanou et al. combined the assessment of placental volume by VOCAL acquisition 
with serum maternal levels of PAPP-a, beta-HCG and UtA-PI at 11-13 weeks’ gestation 
and they found that there is a strong association between low PAPP-a levels and small 
fetal placental volume and this relation was independent from status of conception and 
maternal perfusion (Papastefanou et al., 2014). It could be useful to study placental 
volume in combination with maternal angiogenic and antiangiogenic factors and maternal 
uterine arteries blood flow in pregnancies from IVF technique in the period from 6 to 10 
weeks’ gestation.  
A better understanding of how aberrations in vasculogenesis and angiogenesis may 
impact the manifestation of CHD and associated placental abnormalities will improve our 
ability to predict those fetuses that will have significant growth abnormalities. Moreover, 
the prediction of an increased risk of CHD in the presence of family history or previous 
preeclampsia should bring the clinician to establish preventive measures such as high 
dose of folic acid or in case of low PlGF or PAPP-a detected at the time of the first 
trimester screening for aneuploidies or preeclampsia, the use of low-dose aspirin in the 
prevention of CHD should be assessed.  
At later stage of pregnancy, alternative ways to MCA-PI analysis should be found to 
assess those fetuses who are potentially at risk of poor neurodevelopmental outcome. 
One could be the assessment of the umbilical vein (UV) flow. Sun et al., designed a study 
using phase contrast MRI to evaluate blood flow quantification, fetal brain volumetry and 
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oximetry in fetuses with single ventricle defects, TGA and TOF and they found that a 
reduced UV flow and reduced O2 saturation positively correlates with a reduced cerebral 
O2 delivery and consumption (Sun et al., 2016). Fetal umbilical vein blood flow (UVBF) 
has been assessed by US in pregnancies affected by FGR and has been shown to be a 
more direct surrogate of the amount of oxygen and nutrients reaching the fetus (Parra-
Saavedra et al., 2013; Ferrazzi et al. 2000). This open a new possibility in the field of 
prenatal evaluation of CHD by US: studies of the blood flow in the UV will possibly help 
in understanding the hemodynamic consequences of the cardiac defect on the systemic 
circulation, its relation to placental dysfunction and blood flow to the brain. Concomitant 
assessment of prenatal and postnatal fetal brain volume and function, by functional MRI 
study, and an adequate neonatal follow-up will hopefully help in the definition of those 
CHDs at increased risk of NDD. 
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CHAPTER 8 CONCLUSIONS 
 
The findings of this thesis suggest that in pregnancy with major cardiac defects there is 
placental dysfunction from as early as 11-13 weeks’ gestation in the absence of impaired 
placental perfusion. The presence of an angiogenic imbalance status does not correlate 
to the type of cardiac defect as does not the uterine perfusion. 
 
In the second and third trimester of pregnancy we showed, on a large population, that 
HC is not the only parameter affected by the presence of the CHD but there is a 
symmetrical fetal growth restriction involving all components of the fetuses with moderate 
negative deviations from median values. Uterine arteries perfusion is still within the 
normal range in the second trimester but slightly higher in the third trimester reflecting a 
degree of placental dysfunction. 
 
Analysis of fetal Doppler in the third trimester showed that the presence of placental 
dysfunction is reflected in increased resistance in the umbilical artery without the typical 
pattern of a severe placental insufficiency. The blood flow to the brain, assessed by the 
measurements of the MCA-PI, showed that there is a reactive vasodilation in those 
cardiac defects with a predicted low blood flow and oxygenation to the brain but there is 
a tendency towards higher levels of MCA-PI in those with a predicted normal or increased 
blood flow to the brain, suggesting the presence of a mechanic autoregulation of the 
MCA depending on the quantity of flow more than on quantity of oxygen.  
 
In conclusion, we showed that fetuses with an isolated major congenital heart defect 
have a moderate degree of fetal growth restriction that affects all components of fetal 
body, in the presence of normal uterine perfusion. Such results suggest that the 
presence of fetal growth restriction in fetuses with CHDs is mainly related to a primary 
placental dysfunction supported by abnormal uterine and umbilical arteries Doppler in 
the third trimester. Significance of MCA-PI pattern still need to be clarified, however there 
is some evidence that different autoregulatory mechanism, other than low oxygenation, 
are responsible of MCA-PI in the different type of cardiac defect. 
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